<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">26556</article-id><article-id pub-id-type="doi">10.7554/eLife.26556</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Tuning of in vivo cognate B-T cell interactions by Intersectin 2 is required for effective anti-viral B cell immunity</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-83568"><name><surname>Burbage</surname><given-names>Marianne</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0686-2608</contrib-id><email>marianne.burbage@curie.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">†</xref></contrib><contrib contrib-type="author" id="author-83569"><name><surname>Gasparrini</surname><given-names>Francesca</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83570"><name><surname>Aggarwal</surname><given-names>Shweta</given-names></name><email>shweta.aggarwal@crick.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83571"><name><surname>Gaya</surname><given-names>Mauro</given-names></name><email>mauro.gaya@crick.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-101240"><name><surname>Arnold</surname><given-names>Johan</given-names></name><email>JARNOLD7@mgh.harvard.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83572"><name><surname>Nair</surname><given-names>Usha</given-names></name><email>UNAIR@mgh.harvard.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-78906"><name><surname>Way</surname><given-names>Michael</given-names></name><email>michael.way@crick.ac.uk</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-83573"><name><surname>Bruckbauer</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa2">‡</xref></contrib><contrib contrib-type="author" corresp="yes" id="author-79439"><name><surname>Batista</surname><given-names>Facundo D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1130-9463</contrib-id><email>FBATISTA1@mgh.harvard.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Lymphocyte Biology Laboratory</institution><institution>The Francis Crick Institute</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution>Ragon Institute of MGH, MIT and Harvard</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Cellular Signalling and Cytoskeletal Function Laboratory</institution><institution>The Francis Crick Institute</institution><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-7917"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role>Reviewing Editor</role><aff><institution>University of Oxford</institution><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-1153"><name><surname>Nussenzweig</surname><given-names>Michel C</given-names></name><role>Senior Editor</role><aff><institution>The Rockefeller University</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Institut Curie, Paris, France</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>FILM facility, Imperial College London, London, United Kingdom</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>16</day><month>01</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>7</volume><elocation-id>e26556</elocation-id><history><date date-type="received" iso-8601-date="2017-03-07"><day>07</day><month>03</month><year>2017</year></date><date date-type="accepted" iso-8601-date="2018-01-01"><day>01</day><month>01</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Burbage et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Burbage et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-26556-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.26556.001</object-id><p>Wiskott-Aldrich syndrome (WAS) is an immune pathology associated with mutations in WAS protein (WASp) or in WASp interacting protein (WIP). Together with the small GTPase Cdc42 and other effectors, these proteins participate in the remodelling of the actin network downstream of BCR engagement. Here we show that mice lacking the adaptor protein ITSN2, a G-nucleotide exchange factor (GEF) for Cdc42 that also interacts with WASp and WIP, exhibited increased mortality during primary infection, incomplete protection after Flu vaccination, reduced germinal centre formation and impaired antibody responses to vaccination. These defects were found, at least in part, to be intrinsic to the B cell compartment. In vivo, ITSN2 deficient B cells show a reduction in the expression of SLAM, CD84 or ICOSL that correlates with a diminished ability to form long term conjugates with T cells, to proliferate in vivo, and to differentiate into germinal centre cells. In conclusion, our study not only revealed a key role for ITSN2 as an important regulator of adaptive immune-response during vaccination and viral infection but it is also likely to contribute to a better understanding of human immune pathologies.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>B cells</kwd><kwd>antibody responses</kwd><kwd>B-T interactions</kwd><kwd>SLAM family receptors</kwd><kwd>Wiskott-Aldrich syndrome</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>FC001035</award-id><principal-award-recipient><name><surname>Burbage</surname><given-names>Marianne</given-names></name><name><surname>Gasparrini</surname><given-names>Francesca</given-names></name><name><surname>Aggarwal</surname><given-names>Shweta</given-names></name><name><surname>Bruckbauer</surname><given-names>Andreas</given-names></name><name><surname>Batista</surname><given-names>Facundo D</given-names></name><name><surname>Gaya</surname><given-names>Mauro</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>FC001035</award-id><principal-award-recipient><name><surname>Burbage</surname><given-names>Marianne</given-names></name><name><surname>Gasparrini</surname><given-names>Francesca</given-names></name><name><surname>Aggarwal</surname><given-names>Shweta</given-names></name><name><surname>Bruckbauer</surname><given-names>Andreas</given-names></name><name><surname>Batista</surname><given-names>Facundo D</given-names></name><name><surname>Gaya</surname><given-names>Mauro</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>FC001035</award-id><principal-award-recipient><name><surname>Burbage</surname><given-names>Marianne</given-names></name><name><surname>Gasparrini</surname><given-names>Francesca</given-names></name><name><surname>Aggarwal</surname><given-names>Shweta</given-names></name><name><surname>Bruckbauer</surname><given-names>Andreas</given-names></name><name><surname>Batista</surname><given-names>Facundo D</given-names></name><name><surname>Gaya</surname><given-names>Mauro</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003762</institution-id><institution>Institut Pasteur</institution></institution-wrap></funding-source><award-id>Fondazione Cenci Bolognetti</award-id><principal-award-recipient><name><surname>Gasparrini</surname><given-names>Francesca</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003043</institution-id><institution>EMBO</institution></institution-wrap></funding-source><award-id>ALTF 302-2013</award-id><principal-award-recipient><name><surname>Aggarwal</surname><given-names>Shweta</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>FC001209</award-id><principal-award-recipient><name><surname>Way</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome</institution></institution-wrap></funding-source><award-id>FC001209</award-id><principal-award-recipient><name><surname>Way</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>FC001209</award-id><principal-award-recipient><name><surname>Way</surname><given-names>Michael</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution>The Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery of the National Institutes of Health</institution></institution-wrap></funding-source><award-id>UM1AI100663</award-id><principal-award-recipient><name><surname>Batista</surname><given-names>Facundo D</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Intersectin2 deficiency is associated with impaired humoral responses to viral infection and B-cell-intrisic defects in germinal centre formation, resulting from the reduced ability of intersectin2-KO B cells to establish cognate interactions with helper T cells.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>B lymphocytes play an integral part in humoral immunity through their ability to produce high affinity antibodies in response to infections. Naïve B cells express a unique B cell receptor (BCR) that allows them to recognise cognate antigen, usually on the surface of antigen presenting cells (APCs), such as follicular dendritic cells or subcapsular sinus macrophages (<xref ref-type="bibr" rid="bib3">Batista and Harwood, 2009</xref>; <xref ref-type="bibr" rid="bib13">Cyster, 2010</xref>). Binding of antigen to the BCR triggers a signaling cascade, which provides the first signal for B cell activation (<xref ref-type="bibr" rid="bib32">Kurosaki et al., 2010</xref>). BCR engagement also induces rapid and radical alterations of cellular morphology, coupled to substantial remodelling of the B cell actin network (<xref ref-type="bibr" rid="bib16">Fleire et al., 2006</xref>).</p><p>BCR-induced reorganisation of the actin cytoskeleton plays a central part in the initiation of B cell responses. Consequently, B cells lacking key cytoskeleton regulators, such as the small Rho GTPases Rac1 and Rac2, RhoA or Cdc42, show far-reaching functional impairments (<xref ref-type="bibr" rid="bib22">Guo et al., 2009</xref>; <xref ref-type="bibr" rid="bib5">Burbage et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Gerasimcik et al., 2015</xref>; <xref ref-type="bibr" rid="bib53">Saci and Carpenter, 2005</xref>; <xref ref-type="bibr" rid="bib65">Walmsley et al., 2003</xref>). The activity of Rho GTPases is modulated by G-nucleotide exchange factors (GEFs) that trigger their switch from a GDP-bound inactive to a GTP-bound active state. B cell-intrinsic deletion of the GEFs Vav or dedicator of cytokinesis (DOCK8) severely impairs antibody responses in mice (<xref ref-type="bibr" rid="bib17">Fujikawa et al., 2003</xref>; <xref ref-type="bibr" rid="bib50">Randall et al., 2009</xref>; <xref ref-type="bibr" rid="bib60">Tarakhovsky et al., 1995</xref>). Accordingly, in humans, multiple immune pathologies have been linked to mutations in actin regulators. Mutations in <italic>DOCK8</italic> have been found in independent cohorts of immunodeficient patients (<xref ref-type="bibr" rid="bib40">McGhee and Chatila, 2010</xref>; <xref ref-type="bibr" rid="bib68">Zhang et al., 2009</xref>). Wiskott-Aldrich syndrome (WAS), characterised by recurrent infections and abnormal lymphocyte function is commonly caused by loss-of-function mutations in WAS protein (WASp) or in its interacting protein WIP (<xref ref-type="bibr" rid="bib34">Lanzi et al., 2012</xref>; <xref ref-type="bibr" rid="bib61">Thrasher and Burns, 2010</xref>), both of which are involved in triggering actin polymerisation downstream of Cdc42 (<xref ref-type="bibr" rid="bib38">Martinez-Quiles et al., 2001</xref>; <xref ref-type="bibr" rid="bib43">Moreau et al., 2000</xref>).</p><p>One consequence of BCR signalling is antigen internalisation followed by its processing and presentation onto MHC class II, enabling cognate interactions between activated B cells and CD4 T lymphocytes that recognise antigenic peptide-MHC complexes (<xref ref-type="bibr" rid="bib33">Lanzavecchia, 1985</xref>). These interactions allow B cells to receive T cell help in a contact dependent fashion. The combination of BCR signalling and T cell help is critical for B cells to enter the germinal centre (GC) reaction, during which they undergo somatic hypermutation and class-switch recombination, and from where antibody secreting cells with high affinity for the antigen emerge (<xref ref-type="bibr" rid="bib63">Victora and Mesin, 2014</xref>). The establishment of prolonged contacts between B and T cells rely on interactions between various receptors, such as MHCII and TCR, or CD80/CD86 and CD28 (<xref ref-type="bibr" rid="bib12">Crotty, 2015</xref>). The signalling lymphocytic activation molecule (SLAM) family of transmembrane receptors and the SLAM-associated protein (SAP) family of intracellular adaptors have crucial roles in stabilising B-T conjugates both at the B-T border and in GCs (<xref ref-type="bibr" rid="bib56">Schwartzberg et al., 2009</xref>). In humans, mutations in <italic>SH2D1A</italic> (encoding for SAP) are causative of X-linked lymphoproliferative disease (XLP), an immune pathology characterised by an extreme sensitivity to Epstein Barr Virus infections (<xref ref-type="bibr" rid="bib10">Coffey et al., 1998</xref>; <xref ref-type="bibr" rid="bib54">Sayos et al., 1998</xref>). SAP deficient T cells fail to establish long term conjugates with B cells, resulting in a dramatic block in the generation of high affinity antibodies (<xref ref-type="bibr" rid="bib11">Crotty et al., 2003</xref>; <xref ref-type="bibr" rid="bib14">Czar et al., 2001</xref>; <xref ref-type="bibr" rid="bib48">Qi et al., 2008</xref>). The SLAM receptor CD84 is also required for this process, as CD84 deficient T cells are compromised in their ability to establish stable interactions with B cells (<xref ref-type="bibr" rid="bib6">Cannons et al., 2010</xref>). However, the molecules involved in stabilising these contacts on the B cell side have not been identified.</p><p>Intersectin (ITSN) 2 is a multimodular adaptor protein ubiquitously expressed as two distinct isoforms, ITSN2-S, and the longer isoform ITSN2-L. Both isoforms contain SH3 domains, which support direct interactions with multiple partners, including WASp and WIP (<xref ref-type="bibr" rid="bib21">Gryaznova et al., 2015</xref>), but only ITSN2-L has a GEF domain consistent of a DH (Dbl homology) domain coupled to a PH (Pleckstrin homology) domain (<xref ref-type="bibr" rid="bib47">Pucharcos et al., 2000</xref>). Notably, the GEF activity of ITSN2-L is selective for Cdc42 (<xref ref-type="bibr" rid="bib45">Novokhatska et al., 2011</xref>). Interestingly, in a large-scale association study, <italic>ITSN2</italic> has been identified as a potential at-risk locus for Sjögren’s syndrome, a common autoimmune pathology characterised by keratoconjunctivitis and xerostomia (<xref ref-type="bibr" rid="bib36">Lessard et al., 2013</xref>). Moreover, the <italic>ITSN2</italic> locus has been found to be differentially methylated in B lymphocytes from healthy donors versus cells from Sjögren’s syndrome patients (<xref ref-type="bibr" rid="bib41">Miceli-Richard et al., 2016</xref>).</p><p>In this study, we provide the first characterisation of the role of ITSN2 in the context of immune responses. We show that genetic ablation of ITSN2 rendered mice more sensitive to a lethal infection with Influenza virus. Furthermore, ITSN2 deficient B cells were defective in entering the GC reaction and in generating high affinity antibodies. In vivo, <italic>Itsn2<sup>-/-</sup></italic> B cells exhibited proliferation defects upon immunisation, expressed reduced levels of various surface receptors, and were impaired in forming long-term conjugates with cognate T lymphocytes. The results presented here provide the first characterisation of the role of ITSN2 in the context of immune responses. Furthermore, they identify an essential function for this protein in the regulation of B-T cell interactions, germinal centre formation and antibody production, which is reminiscent of the phenotype associated with SAP or CD84 deficiency in T cells.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>B and T cells develop normally in <italic>Itsn2<sup>-/-</sup></italic> mice</title><p>Due to the intricate relationship between BCR signalling, the actin cytoskeleton and its regulators, we sought to characterize the role of ITSN2 in mouse immune responses. To analyse the function of ITSN2 in B cells, we obtained ITSN2 deficient mice from the Knockout Mouse Project (KOMP) consortium. These animals were generated using the Velocigene technology; they carry a LacZ reporter cassette knocked into the <italic>Itsn2</italic> locus, disrupting the expression of this gene, and a selectable neomycin marker that was subsequently be excised by Cre recombinase (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, [<xref ref-type="bibr" rid="bib58">Skarnes et al., 2011</xref>; <xref ref-type="bibr" rid="bib62">Valenzuela et al., 2003</xref>]). ITSN2 is a multimodular adaptor protein with two alternative stop codons yielding functionally distinct isoforms, ITSN2-L and ITSN2-S, with only ITSN2-L bearing a GEF domain (DH-PH) (<xref ref-type="bibr" rid="bib47">Pucharcos et al., 2000</xref>). While we could detect the expression of both ITSN2 isoforms in wild type (WT) B cells, this expression was abolished in B cells from the ITSN2 knockout (Itsn2tm1.1(KOMP) Vlcg) animals, hereafter referred to as <italic>Itsn2<sup>-/-</sup></italic> (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.26556.002</object-id><label>Figure 1.</label><caption><title>Lymphocyte development is not compromised by ITSN2 deletion.</title><p>(<bold>A</bold>) Genetic approach used to delete ITSN2. A LacZ cassette was inserted in the <italic>Itsn2</italic> locus to disrupt protein expression. A neomycin resistance cassette flanked by two loxP sites was used as a selection marker, and subsequently excised by Cre-mediated recombination (KOMP allele tm1.1). (<bold>B</bold>) Naïve B cells were purified from the spleens of WT and <italic>Itsn2<sup>-/-</sup></italic> mice and protein expression of ITSN2 (upper immunoblot, two isoforms as illustrated on the right) and clathrin heavy chain (lower immunoblot) were detected by Western blot. (<bold>C</bold>) Bone marrow from WT and <italic>Itsn2<sup>-/-</sup></italic> littermates was analysed by flow cytometry using the gating strategy shown on the left. B cell progenitors (B220<sup>+</sup>) were divided into immature (CD43<sup>+</sup>) and mature (CD43<sup>-</sup>) cells on the basis of CD43 expression. Data quantified in the panels on the right show the percentage of live cells in the indicated gates. (<bold>D</bold>) Thymus from WT and <italic>Itsn2<sup>-/-</sup></italic> littermates were analysed by flow cytometry. Gating strategy is shown on the left. T cell progenitors (CD3<sup>+</sup>) were divided into double negative (CD4<sup>-</sup> CD8<sup>-</sup>), double positive (CD4<sup>+</sup> CD8<sup>+</sup>), CD4 single positive (CD4<sup>+</sup> CD8<sup>-</sup>) and CD4 single positive (CD4<sup>-</sup> CD8<sup>+</sup>) cells. Data quantified in the panels on the right show the percentage of CD3<sup>+</sup> cells in the indicated gates. (<bold>E–H</bold>) Spleens from WT and <italic>Itsn2<sup>-/-</sup></italic> were analysed by flow cytometry. (<bold>E</bold>) Identification and quantification of B cells (B220<sup>+</sup> TCRβ<sup>−</sup>) and T cells (B220<sup>-</sup> TCRβ<sup>+</sup>). (<bold>F</bold>) T cells were subdivided into CD4 (CD4<sup>+</sup> CD8<sup>-</sup>) and CD8 (CD4<sup>-</sup> CD8<sup>+</sup>) T cells and quantified. (<bold>G–H</bold>) B cells were divided on the basis of CD21, CD23 and CD24 expression into T0/T1 cells (CD21<sup>-</sup>CD24<sup>hi</sup>, <bold>G</bold>), follicular B cells (CD21<sup>lo</sup>CD24<sup>lo</sup>, <bold>G</bold>), T2 cells (CD21<sup>hi</sup> CD24<sup>hi</sup> CD23<sup>-</sup>, <bold>H</bold>), MZB cells (CD21<sup>hi</sup> CD24<sup>hi</sup> CD23<sup>+</sup>, <bold>H</bold>) and quantified (right panels). For all flow cytometry experiments (<bold>C–G</bold>), data are from 1 out of 3 representative experiment with 4 or more animals in each group, and each dot represents an individual mouse. Student’s t-test, ns p&gt;0.05, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26556-fig1-v1"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26556.003</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Lymphocyte development is not compromised by ITSN2 deletion.</title><p>(<bold>A–B</bold>) Bone marrow from WT and <italic>Itsn2<sup>-/-</sup></italic> littermates was analysed by flow cytometry. Gating strategy is shown on the left. B cell progenitors (B220<sup>+</sup>) were divided into early (CD43<sup>+</sup>) and late (CD43<sup>-</sup>) cells on the basis of CD43 expression. (<bold>A</bold>) Early (CD43<sup>+</sup>) B cell progenitors were subdivided according to CD24 and BP-1 expression into Hardy populations A (CD24<sup>-</sup>BP-1<sup>-</sup>), B (CD24<sup>+</sup>BP-1<sup>-</sup>) and C (CD24<sup>+</sup>BP-1<sup>+</sup>). Data quantified in the panels on the right show the percentage of CD43<sup>+</sup> cells in the indicated gates. (<bold>B</bold>) Late (CD43<sup>-</sup>) B cell progenitors were subdivided according to IgM and IgD expression into Hardy populations D (IgM<sup>-</sup>IgD<sup>-</sup>), E (IgM<sup>+</sup> IgD<sup>int</sup>) and F (IgM<sup>+</sup>IgD<sup>+</sup>). The data quantified in the panels on the right show the percentage of CD43<sup>-</sup> cells in the indicated gates. (<bold>C</bold>) Peritoneal lavage was performed on WT and <italic>Itsn2<sup>-/-</sup></italic> littermates, and the exudate was analysed by flow cytometry. B cells (IgM<sup>+</sup>) were divided into B2 (CD11b<sup>-</sup>CD5<sup>-</sup>), B1b (CD11b<sup>+</sup>CD5<sup>-</sup>) and B1a (CD11b<sup>+</sup>CD5<sup>+</sup>). Data quantified in the panels on the right show the percentage of IgM<sup>+</sup> cells in the indicated gates. Data are from 1 out of 3 experiments with 5 or more animals in each group. Student’s t-test, ns – p&gt;0.05. (<bold>D</bold>) Serum from naïve age-matched WT and <italic>Itsn2<sup>-/-</sup></italic> animals was collected and baseline antibody titres were measured by sandwich ELISA. Data are pooled from two independent experiments with more than four animals in each group. Student’s t-test, ns p&gt;0.05.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig1-figsupp1-v1"/></fig></fig-group><p>To examine the effect of ITSN2 deletion on early lymphocyte development, we extracted bone marrow (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) or thymus (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) cells from 8 to 12 week-old WT and <italic>Itsn2<sup>-/-</sup></italic> mice and analysed them by flow cytometry. B cell progenitors were analysed using the Hardy classification system (<xref ref-type="bibr" rid="bib23">Hardy et al., 1991</xref>). Bone marrow cellularity was largely unaltered by ITSN2 deletion, and we found similar numbers of early (B220<sup>+</sup>CD43<sup>+</sup>) and late (B220<sup>+</sup>CD43<sup>-</sup>) B cell progenitors in bone marrows from WT and <italic>Itsn2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Moreover, we did not detect any differences in frequencies of the Hardy populations A (CD43<sup>-</sup> CD24<sup>-</sup> BP-1<sup>-</sup>), B (CD43<sup>hi</sup> CD24<sup>+</sup> BP-1<sup>-</sup>), C (CD43<sup>-</sup> CD24<sup>+</sup> BP-1<sup>+</sup>), D (CD43<sup>-</sup> IgM<sup>-</sup> IgD<sup>-</sup>), E (CD43<sup>-</sup> IgM<sup>+</sup> IgD<sup>-</sup>) and F (CD43<sup>-</sup> IgM<sup>+</sup> IgD<sup>hi</sup>) cells upon ITSN2 deletion (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and B</xref>). This suggests that lack of ITSN2 does not compromise the ability of B cells to undergo rearrangements of the BCR heavy and light chain loci (stages A-B and D, respectively) and subsequent positive selection and proliferation (stage C and E, respectively). In the thymus, T cell progenitors (CD3<sup>+</sup>) are subdivided on the basis of CD4 and CD8 expression into double negative (CD4<sup>-</sup>CD8<sup>-</sup>), double positive (CD4<sup>+</sup>CD8<sup>+</sup>), CD4 single positive (CD4<sup>+</sup>CD8<sup>-</sup>) and CD8 single positive (CD4<sup>-</sup>CD8<sup>+</sup>). These four populations were found in comparable numbers in WT and <italic>Itsn2<sup>-/-</sup></italic> animals. (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). These results indicate that ITSN2 is not required for early lymphoid development.</p><p>To examine the impact of ITSN2 deletion on lymphocyte populations on secondary lymphoid organs, we analysed the spleens of 8–10 week old WT and <italic>Itsn2<sup>-/-</sup></italic> littermates by flow cytometry. We detected comparable numbers of B and T cells in animals from both genotypes (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). However, we detected a small increase in the fraction of CD4 T cells mirrored by a decrease in that of CD8 T cells in <italic>Itsn2<sup>-/-</sup></italic> mice compared to WT animals (<xref ref-type="fig" rid="fig1">Figure 1F</xref>).</p><p>To characterise the progression of transitional B cells towards fully mature B lymphocytes, we analysed single cell suspensions from the spleens of WT and <italic>Itsn2<sup>-/-</sup></italic> mice by flow cytometry. Within the B cell compartment, we found comparable proportions of T1 cells (B220<sup>+</sup>CD21<sup>lo</sup>CD24<sup>hi</sup>), suggesting that homing of immature B cells to the spleen is not compromised by ITSN2 deletion. In contrast, there was a 50% reduction in numbers of T2 (B220<sup>+</sup>CD21<sup>hi</sup>CD24<sup>hi</sup> CD23<sup>+</sup>) B cells upon ITSN2 deletion (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). As the survival of T2 cells is highly dependent on BCR and BAFF-mediated signalling, these results suggest that <italic>Itsn2<sup>-/-</sup></italic> T2 B cells may have a defect in sensing these signals (<xref ref-type="bibr" rid="bib24">Hsu et al., 2002</xref>; <xref ref-type="bibr" rid="bib55">Schiemann et al., 2001</xref>). However, <italic>Itsn2<sup>-/-</sup></italic> B cells retained some maturation potential, as we found similar amounts of both mature follicular (B220<sup>+</sup>CD21<sup>hi</sup>CD24<sup>lo</sup>) and marginal zone B cells (B220<sup>+</sup>CD21<sup>hi</sup>CD24<sup>hi</sup>CD23<sup>-</sup>) in WT and <italic>Itsn2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>). Moreover, WT and <italic>Itsn2<sup>-/-</sup></italic> animals had comparable numbers of B2 (CD5<sup>-</sup>CD11b<sup>-</sup>), B1a (CD5<sup>+</sup>CD11b<sup>+</sup>) and B1b (CD5<sup>-</sup>CD11b<sup>+</sup>) cells in the peritoneal cavity (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Concordant with these results, basal titres of IgM, IgG1, IgG2b and IgG2c were comparable in WT and <italic>Itsn2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Together, these results suggest that ITSN2 is broadly dispensable for the establishment of mature lymphocyte populations.</p></sec><sec id="s2-2"><title>Higher susceptibility to viral infection and diminished germinal centre formation in <italic>Itsn2<sup>-/-</sup></italic> mice</title><p>In order to determine the physiological consequences of ITSN2 deletion, we intranasally infected 12–16 weeks WT and <italic>Itsn2<sup>-/-</sup></italic> littermates with a lethal dose (3 × 10<sup>4</sup> PFU) of the Influenza A virus (PR8 strain). Post-infection, we followed the survival of these animals by weighing them daily and sacrificing the ones that exhibited 20% weight loss. We found that 4 and 5 days after viral infection, <italic>Itsn2<sup>-/-</sup></italic> mice showed significantly lower body weight than their WT counterparts (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). As a result, the survival of the ITSN2 KO animals was reduced (p=0.0345) compared to that of WT littermates upon influenza infection (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Indeed, the first <italic>Itsn2<sup>-/-</sup></italic> animals were sacrificed as early as 3 days post infection, while the majority of WT animals survived until day six post-infection. These results suggest that ITSN2 is required for mounting a robust response to viral infection.</p><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.26556.004</object-id><label>Figure 2.</label><caption><title><italic>Itsn2<sup>-/-</sup></italic> animals are impaired in responding to viral infection.</title><p>(<bold>A–B</bold>) Age-matched WT and <italic>Itsn2<sup>-/-</sup></italic> mice were infected intranasally with 3 × 10<sup>4</sup> PFU of Influenza virus (PR8 strain). Animals were weighed daily and culled when exhibiting 20% weight loss compared to the weight at Day 0. Survival curve (<bold>A</bold>) and weight loss (<bold>B</bold>) as a function of days post infection are shown. Survival analysis, p=0.0345. (<bold>C</bold>) Age-matched WT and <italic>Itsn2<sup>-/-</sup></italic>mice were vaccinated by i.v infection of Hemagglutinin trimer with Sigma Adjuvant. After one month, mice were infected with 1.5.10<sup>5</sup> PFU Influenza PR8 and weighed daily for the whole duration of the experiment. (<bold>D–G</bold>) WT and <italic>Itsn2<sup>-/-</sup></italic> littermates were infected with 10<sup>4</sup> PFU Vaccinia virus (Western Reserve), and draining popliteal lymph nodes were analysed by flow cytometry 7 days post-infection. B cells (CD19<sup>+</sup>, <bold>D</bold>), GC (B220<sup>+</sup> GL-7<sup>+</sup> CD95<sup>+</sup>, <bold>E</bold>), CD4 T cells (CD4<sup>+</sup>, <bold>F</bold>) and activated T cells (CD4<sup>+</sup>CD44<sup>+</sup>CD62L<sup>-</sup>, <bold>G</bold>) are shown. Student’s t-test, ns p&gt;0.05, *p&lt;0.05.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig2-v1"/></fig><p>To further define the role of ITSN2 in the establishment of protective responses, we immunised WT and <italic>Itsn2<sup>-/-</sup></italic> mice with hemagglutinin trimer (<xref ref-type="bibr" rid="bib30">Koday et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Zheng et al., 2016</xref>). After one month, animals were challenged with a lethal dose (1.5 × 10<sup>5</sup>) of Influenza PR8. Upon such challenge, non-immunised WT animals lost weight rapidly, and had to be sacrificed within 1 week of infection (data not shown). Immunised WT animals also exhibited rapid weight loss, but started to regain weight 9 days after infection. In contrast, immunised <italic>Itsn2<sup>-/-</sup></italic> animals lost weight at similar rate as their WT counterparts, and their weight remained low until d14 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). These results indicate that vaccinated <italic>Itsn2<sup>-/-</sup></italic> animals fail to control the infection compared to WT vaccinated mice. Hence, these results support the notion that ITSN2 is required for establishing protective immune responses against viral infection.</p><p>To gain insights into which cellular processes underlying the humoral immune response were impaired in <italic>Itsn2<sup>-/-</sup></italic> mice, we infected WT and <italic>Itsn2<sup>-/-</sup></italic> animals with a sub-lethal dose of 10<sup>4</sup> PFU Vaccinia virus (Western reserve) via intra-footpad injection and analysed the popliteal lymph nodes by flow cytometry 7 days after infection. We found similar numbers of CD19<sup>+</sup> B cells in animals from both genotypes indicating that ITSN2 inactivation does not compromise B cell survival under these conditions (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). However, when we examined the expansion of CD95<sup>+</sup> GL-7<sup>+</sup> germinal centre (GC) B cells after Vaccinia infection by flow cytometry analysis, we found a 40% reduction in B cells engaged in the GC reaction in <italic>Itsn2<sup>-/-</sup></italic> mice compared with their WT littermates (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). In contrast, we did not discern a difference in the CD4 T cell compartment of WT versus <italic>Itsn2<sup>-/-</sup></italic> animals; indeed, we observed similar proportions of naïve (CD44<sup>-</sup>CD62L<sup>+</sup>) T cells and activated (CD44<sup>+</sup>CD62L<sup>-</sup>) T cells (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>). These experiments show that ITSN2 plays an important role in the generation of B cell responses upon viral infection.</p></sec><sec id="s2-3"><title>GC B cells, but not Tfh cells, are impaired in the absence of ITSN2 after vaccination</title><p>To further dissect immune responses in an <italic>Itsn2</italic>-deficient context, we immunised WT and <italic>Itsn2<sup>-/-</sup></italic> mice i.p. with the hapten NP conjugated to KLH in alum, a model T cell-dependent antigen, and analysed the splenic B cell compartment 13 days after immunisation. We detected a robust induction of antigen-specific GC B cells (NP<sup>+</sup>CD95<sup>+</sup>GL7<sup>+</sup>) in WT animals, which was 5-fold lower in <italic>Itsn2<sup>-/-</sup></italic> animals (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Interestingly, 82% of <italic>Itsn2<sup>-/-</sup></italic> GC B cells harboured a DZ profile in comparison with only 67% of their WT counterparts (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). In contrast, there was an approximately two-fold reduction in LZ GC fraction in <italic>Itsn2<sup>-/-</sup></italic> compared to WT animals (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), supporting the notion that ITSN2 is required for B cell progression during the GC reaction. To analyse germinal centre anatomy, we imaged splenic cryosections stained with antibodies against TCRβ (green), B220 (blue) and GL-7 (magenta) to visualise T cell area, B cell follicles and GCs. Interestingly, in sections from <italic>Itsn2<sup>-/-</sup></italic> animals, fewer B cell follicles contained GCs than in the ones from the WT (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Moreover, where GCs were present, they were significantly smaller in <italic>Itsn2<sup>-/-</sup></italic> animals than in their WT counterparts (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><fig-group><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.26556.005</object-id><label>Figure 3.</label><caption><title>Defective humoral responses in <italic>Itsn2<sup>-/-</sup></italic> animals.</title><p>WT and <italic>Itsn2<sup>-/-</sup></italic> littermates were immunised with NP-KLH precipitated in Alum, and B cell responses analysed 13d after immunisation. (<bold>A, B and C</bold>) Spleens of immunised animals were analysed by flow cytometry. Antigen-specific GC B cells (NP<sup>+</sup> GL-7<sup>+</sup> CD95<sup>+</sup>, <bold>A</bold>), Dark zone GC B cells (GL-7<sup>+</sup> CD95<sup>+</sup> CD86<sup>lo</sup>CXCR4<sup>hi</sup>, <bold>B</bold>), light zone GC B cells (GL-7<sup>+</sup> CD95<sup>+</sup> CD86<sup>hi</sup>CXCR4<sup>lo</sup>, <bold>B</bold>). Panels on the right show the show percentage of cells in the indicated gates (each dot represents a different animal). (<bold>C</bold>) Tiled images of spleen frozen sections acquired by confocal microscopy. GC cells (GL7<sup>+</sup>, magenta), B cell area (B220<sup>+</sup>, blue) and T cell area (TCRβ<sup>+</sup>, green) are shown. Scale bars – 200 µm. Quantification in the two right panels indicate the percentage of B cell follicles with a germinal centre (each dot corresponds to one section), and the ratio between GC area and total follicle area (each dot represents an individual B cell follicle). (<bold>D–G</bold>) WT and <italic>Itsn2<sup>-/-</sup></italic> littermates were immunised with NP-KLH precipitated in Alum. (<bold>D</bold>) Serum was collected from WT and <italic>Itsn2<sup>-/-</sup></italic> mice and titres of NP<sub>23</sub>-specific IgM and IgG3 measured by ELISA. (<bold>E</bold>) Serum from WT and <italic>Itsn2<sup>-/-</sup></italic> mice was collected and titres of NP<sub>23</sub>-specific or total IgG and IgG1 were measured by ELISA. (<bold>F</bold>) ELISA analysis showing affinity maturation (expressed as the ratio of NP3 to NP23 titres) of total IgG and IgG1 isoform after immunisation. (<bold>G</bold>) Immunised WT and <italic>Itsn2<sup>-/-</sup></italic> animals were submitted to a secondary challenge at day 80 with NP-KLH in PBS, and titres of NP<sub>23</sub>-specific total IgG and IgG1 were measured by ELISA. Data are representative of at least 2 independent experiments with more than three animals in each group. Student’s t-test, ns p&gt;0.05, *p&lt;0.05, *p&lt;0.01, ***p&lt;0.0001.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig3-v1"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26556.006</object-id><label>Figure 3—figure supplement 1.</label><caption><title>Defective humoral responses in <italic>Itsn2<sup>-/- </sup></italic>animals</title><p>(<bold>A</bold>) WT and <italic>Itsn2<sup>-/-</sup></italic> littermates were immunised with NP-KLH precipitated in Alum, and spleens of immunised animals analysed by flow cytometry 13d after immunisation. Tfh cells (CD4<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>). Panels on the right show the show percentage of cells in the indicated gates (each dot represents a different animal). (<bold>B</bold>) WT and <italic>Itsn2<sup>-/-</sup></italic> littermates were immunised with NP-KLH precipitated in Alum, and 13 days post-immunisation, NP-specific antibody secreting cells were detected in the spleen by ELISPOT. (<bold>F</bold>) WT and <italic>Itsn2<sup>-/-</sup></italic> littermates were immunised with NP-LPS and titres of NP<sub>23</sub>-specific IgM and IgG3 were measured by ELISA. Data are representative of at least 2 independent experiments with more than three animals in each group. Student’s t-test, ns p&gt;0.05, *p&lt;0.05, * p&lt;0.01, *** p&lt;0.0001.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig3-figsupp1-v1"/></fig></fig-group><p>An integral part of a functional GC reaction is the appearance of T follicular helper (Tfh) cells. These are the main subset of T helper (Th) cells that provide costimulatory signals to B cells (<xref ref-type="bibr" rid="bib64">Vinuesa and Cyster, 2011</xref>). In WT animals immunised with NP-KLH, we observed a defined PD1<sup>+</sup>CXCR5<sup>+</sup> Tfh population (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Surprisingly, <italic>Itsn2<sup>-/-</sup></italic> animals consistently presented a 2-fold increase in the number of Tfh cells compared to WT animals (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). These results indicate that the reduction observed in GC formation upon ITSN2 deletion might not result from lack of Tfh cells, instead it is likely to be associated with intrinsic B cell impairment.</p><p>Quantifying the titres of NP-specific antibodies in the serum of immunised mice, we found that titres of the early isotypes IgM and IgG3 were reduced by 2 and 4-fold respectively in <italic>Itsn2<sup>-/-</sup></italic> mice at d7, but not at d14 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Moreover, at d13 post-immunisation, we detected a 3-fold decrease in the numbers of plasma cells secreting NP-specific IgG in the spleen of <italic>Itsn2<sup>-/-</sup></italic> mice compared to WT controls, suggesting a potential impairment in the generation of class-switched antibodies (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Accordingly, NP-specific IgG and IgG1 titres were significantly reduced (2 and 4-fold respectively) in the serum of <italic>Itsn2<sup>-/-</sup></italic> animals compared to WT littermates (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). To test whether these antibodies had undergone affinity maturation, we compared the binding efficiency of the IgGs present in the sera of immunised mice to NP3-BSA and NP23-BSA. The NP3/NP23 ratio (read-out for affinity maturation) increased steadily in WT mice, but it was two to three time lower in the <italic>Itsn2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). This indicates that ITSN2 is required for the generation of high affinity antibodies upon immunisation. To measure the consequences of ITSN2 deletion on B cell memory, animals were submitted to a secondary challenge 3 months after primary immunisation. <italic>Itsn2<sup>-/-</sup></italic> animals presented with 2–3-fold decreased memory titres of total IgG and IgG1, and were severely impaired in mounting secondary responses (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). Taken together, these results show that ITSN2 deletion compromises the production of antigen-specific antibodies in response to T-dependent antigen. To evaluate the function of ITSN2 during T- independent responses, we immunised WT and <italic>Itsn2<sup>-/-</sup></italic> mice with NP-LPS, and measured NP-specific antibodies at d4 and d7 post-immunisation. At both time points, titres of IgM, but not IgG3 were significantly reduced in <italic>Itsn2<sup>-/-</sup></italic> mice compared to WT controls (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>). Together, this set of results highlights the importance of ITSN2 in early and T-independent IgM production, and in the generation of high affinity antibodies upon immunisation.</p></sec><sec id="s2-4"><title>Immunodeficiency observed in <italic>Itsn2<sup>-/-</sup></italic> animals is associated with B cell intrinsic defects</title><p>As the results thus far were obtained with ITSN2 constitutive knockout mice, we wanted to test whether immunodeficiency presented by these animals was associated with B cell intrinsic defects. Accordingly, we generated chimeric mice, wherein lethally irradiated µMT animals lacking mature B cells were injected with a mixture of 80% µMT bone marrow (BM) and 20% WT (WT chimeras) or 20% <italic>Itsn2<sup>-/-</sup></italic> (KO chimeras) BM (<xref ref-type="bibr" rid="bib29">Kitamura et al., 1991</xref>). In KO chimeras, all newly generated B cells will be <italic>Itsn2<sup>-/-</sup></italic> in an environment containing mainly WT immune cells. After 8 weeks, blood samples were collected to test the reconstitution efficiency by flow cytometry. We observed comparable numbers of B cells in WT and <italic>Itsn2<sup>-/-</sup></italic> chimeras, indicating that ITSN2 is not required for bone marrow engraftment under these conditions (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>)</p><p><italic>Itsn2<sup>-/-</sup></italic> and WT chimeric mice were immunized with NP-KLH in alum and bled weekly for 28 days. We measured antibody titres in the serum of WT and <italic>Itsn2<sup>-/-</sup></italic> chimeric mice by ELISA. Noticeably, we observed a severe decrease (3 and 5-fold at d28) in total IgG and IgG1 NP-specific titres in the <italic>Itsn2<sup>-/-</sup></italic> compared to the WT chimeric animals (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). To selectively detect antibodies with high affinity to NP, we used NP4-BSA as capture ligand, and observed a marked decrease in titres of high affinity IgG and IgG1 in<italic> Itsn2<sup>-/-</sup></italic> chimeric animals compared to their WT counterparts (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). These results indicate that selective absence of ITSN2 in the B cell compartment is sufficient to impair antibody responses to T-dependent immunisation.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.26556.007</object-id><label>Figure 4.</label><caption><title><italic>Itsn2<sup>-/-</sup></italic> B cells are intrinsically impaired in responding to immunisation.</title><p>(<bold>A–C</bold>) Lethally irradiated μMT hosts were reconstituted for 10 weeks with mixtures of 80% μMT BM and 20% WT or <italic>Itsn2<sup>-/-</sup></italic> BM and immunised with NP-KLH in Alum. NP<sub>20</sub> (<bold>A</bold>) and NP<sub>4</sub> (<bold>B</bold>)-specific titres were determined by ELISA. (<bold>C–D</bold>) Spleens of immunised animals were analysed by flow cytometry 13 days after immunisation. Antigen-specific GC B cells (NP<sup>+</sup> GL-7<sup>+</sup> CD95<sup>+</sup>, <bold>C</bold>) and Tfh (CD4<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>, <bold>D</bold>) are shown. Quantification shown on the right represent the percentage of cells in the indicated gate. (<bold>E–F</bold>) Lethally irradiated C57BL6-CD45.1 hosts were reconstituted for 10 weeks with mixtures of 50% WT-CD45.1 BM and 50% WT or <italic>Itsn2<sup>-/-</sup></italic> BM, immunised with NP-KLH in Alum, and spleens of immunised animals were analysed by flow cytometry at day 13. CD45.1<sup>+</sup> and CD45.2<sup>+</sup> NP-specific GC B cells (NP<sup>+</sup> GL-7<sup>+</sup> CD95<sup>+</sup>, <bold>E</bold>) and Tfh (CD4<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>, <bold>F</bold>) are shown. Graphs on the right represent the CD45.2/CD45.1 ratio calculated from the percentages of cells in the indicated gates. (<bold>G</bold>) 80–20% mixed chimeras in µMT recipients were infected with 10<sup>4</sup> PFU of Vaccinia virus via intra-footpad injections, and popliteal lymph nodes were analysed by flow cytometry at d7. GC (GL-7<sup>+</sup> CD95<sup>+</sup>, <bold>G</bold>) and Tfh cells (GL-7<sup>+</sup> CD95<sup>+</sup>, <bold>H</bold>) are shown. Data are representative of 2–3 independent experiments with at least 4 mice in each group. Student’s t-test, ns p&gt;0.05, *p&lt;0.05, *p&lt;0.01, ***p&lt;0.0001.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26556-fig4-v1"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26556.008</object-id><label>Figure 4—figure supplement 1.</label><caption><title>Immune compartment reconstitution by <italic>Itsn2<sup>-/-</sup></italic>c<italic>ells</italic> </title><p>(<bold>A</bold>) Lethally irradiated μMT hosts were reconstituted with mixtures of 80% μMT BM and 20% WT or <italic>Itsn2<sup>-/-</sup></italic> BM. After 10 weeks, animals were bled and circulating B (CD19<sup>+</sup>) and T (TCRβ<sup>+</sup>) lymphocytes characterised by flow cytometry. (<bold>B–C</bold>) Lethally irradiated B. CD45.1 hosts were reconstituted with mixtures of 50% B. CD45.1 and 50% WT or <italic>Itsn2<sup>-/-</sup></italic> BM. After 10 weeks, animals were bled and circulating cells were characterised by flow cytometry. (<bold>B</bold>) Circulating cells were divided into CD45.1<sup>+</sup> (WT) and CD45.2<sup>+</sup> (WT or <italic>Itsn2<sup>-/-</sup></italic>). (<bold>C</bold>) CD45.2 cells were subdivided into B (CD19<sup>+</sup>) and T (TCRβ) lymphocytes. For all panels in this figure, data are quantified on the right panels and indicate percentage of live (<bold>A and B</bold>) or CD45.2 (<bold>C</bold>) cells in the indicated gates. Data are from 1 out of at least 3 experiments with 5 animals or more in each group. Student’s t-test, ns p&gt;0.05, *p&lt;0.05.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig4-figsupp1-v1"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26556.009</object-id><label>Figure 4—figure supplement 2.</label><caption><title><italic>Itsn2<sup>-/-</sup> </italic>B cells are intrinsically impaired in responding to immunisation</title><p>(<bold>A–B</bold>) 50–50% mixed chimeras in CD45.1 recipients were infected with 10<sup>4</sup> PFU of Vaccinia virus via intra-footpad injections, and popliteal lymph nodes were analysed by flow cytometry at d7. CD45.1<sup>+</sup> and CD45.2<sup>+</sup> GC B cells (GL-7<sup>+</sup> CD95<sup>+</sup>, (<bold>A</bold>) and Tfh cells (CD4<sup>+</sup>CXCR5<sup>+</sup>PD-1<sup>+</sup>, (<bold>B</bold>) are shown. Graphs on the right represent the CD45.2/CD45.1 ratio calculated from the percentages of cells in the indicated gates.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig4-figsupp2-v1"/></fig></fig-group><p>In the constitutive <italic>Itsn2<sup>-/-</sup></italic> mice, impaired antibody production is associated with defective differentiation of GC B cells. To test whether a similar correlation could be established in chimeric mice, we immunised WT and <italic>Itsn2<sup>-/-</sup></italic> µMT chimeras with NP-KLH in Alum, and measured B cell responses in the spleen after 13 days by flow cytometry. In WT chimeras, we detected a robust induction of GC B cells (CD95<sup>+</sup>GL-7<sup>+</sup>NP<sup>+</sup>) whereas in ITSN2 chimeras, the size of this population was 3-fold diminished compared to the WT (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). However, differentiation of Tfh cells was not impaired in <italic>Itsn2<sup>-/-</sup></italic> chimeras compared to WT ones (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). These results suggest that although <italic>Itsn2<sup>-/-</sup></italic> B cells are severely compromised in entering the GC reaction, they are still able to promote the differentiation and survival of Tfh cells as efficiently as WT B cells.</p><p>To test how <italic>Itsn2<sup>-/-</sup></italic> B cells behaved in competitive settings, we reconstituted lethally irradiated congenic B6.CD45.1 animals with a 50% of CD45.1 BM and 50% of WT CD45.2 (WT-WT) or 50% of <italic>Itsn2<sup>-/-</sup></italic> CD45.2 (WT-<italic>Itsn2<sup>-/-</sup></italic>) BM. The reconstitution efficiency was analysed by flow cytometry 8 weeks after adoptive transfer. While we found comparable proportions of total circulating CD45.2 cells in both types of chimeras, there was a 10% reduction in the fraction of CD45.2 B cells in WT-<italic>Itsn2<sup>-/-</sup></italic>versus WT-WT chimeras (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>). This suggests that under these conditions, WT cells partially outcompete <italic>Itsn2<sup>-/-</sup></italic> cells for access to the mature B cell niche. We immunised these animals with NP-KLH in alum and characterised the GC B cell compartment after 13 days. More specifically, we compared the proportion of B cells engaged in the GC reaction in the CD45.1 (WT) and CD45.2 (WT or <italic>Itsn2<sup>-/-</sup></italic>) in each animal. The CD45.2/CD45.1 ratio was used as a read-out to compare the ability of WT and <italic>Itsn2<sup>-/-</sup></italic> B cells to compete with the CD45.1 WT cells present in the same animal. Notably, <italic>Itsn2<sup>-/-</sup></italic> B cells were selectively impaired in GC formation (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), but Tfh differentiation was not affected (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). These results provide further evidence to support the notion that <italic>Itsn2<sup>-/-</sup></italic> B cells are intrinsically impaired in engaging in the germinal centre reaction and in generating high affinity antibodies after immunisation.</p><p>To test whether <italic>Itsn2<sup>-/-</sup></italic> B cells were also impaired in responding to viral infection, we infected 80–20 chimeras in µMT or 50–50 chimeras in B6.CD45.1 with Vaccinia virus injected intra-footpad and characterised the immune response in the draining popliteal lymph node 7 days later. In both cases, chimeras reconstituted with <italic>Itsn2<sup>-/-</sup></italic> bone marrows showed decreased numbers of GC B cells compared to their WT counterparts (<xref ref-type="fig" rid="fig4">Figure 4G</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A</xref>), although the number of Tfh cells was comparable between the two (<xref ref-type="fig" rid="fig4">Figure 4H</xref> and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>).</p><p>Together, these results demonstrate that ITSN2 expression in the B cell compartment is required for B cell engagement into the GC response, and for the generation of high affinity antibodies upon immunisation.</p></sec><sec id="s2-5"><title><italic>Itsn2<sup>-/-</sup></italic> B cells are defective at BCR signalling</title><p>The strong immunodeficiency that we observed in <italic>Itsn2<sup>-/-</sup></italic> animals raises the question of whether this molecule is required for biochemical and cellular responses downstream of the BCR. ITSN2 contains several tyrosine residues that can be phosphorylated upon stimulation with estrogen growth factor (EGF) (<xref ref-type="bibr" rid="bib46">Novokhatska et al., 2013</xref>). To check whether BCR ligation caused alterations in ITSN2 phosphorylation status, we stimulated purified naïve B cells with anti-IgM F(ab’)<sub>2</sub> for 0, 1, 5 or 15 min. Next, cells were lysed and immunoprecipitation was carried out using an anti-phospho-tyrosine antibody. Western blot analysis revealed that both isoforms of ITSN2 were rapidly phosphorylated after BCR stimulation (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), suggesting a potential role for the phosphorylation of this molecule in the BCR signalling cascade.</p><fig-group><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.26556.010</object-id><label>Figure 5.</label><caption><title>ITSN2 participates in the BCR signalling cascade.</title><p>(<bold>A</bold>) Purified naïve B cells were stimulated with anti-IgM F(ab’)<sub>2</sub> (10 µg mL<sup>−1</sup>) for 0, 1, 5 or 15 min, the total phosphotyrosine fraction was immunoprecipitated, and phosphorylated ITSN2 detected by Western blot. Quantification below shows phosphorylated ITSN2 intensity related to β-Actin. Data are representative of 3 independent experiments. (<bold>B</bold>) A20 cells with a HEL-specific BCR were transfected with a plasmid encoding for ITSN2-L GFP, settled onto fluorescently labelled antigen-loaded lipid bilayers and imaged with a TIRF microscope. Localisation of ITSN2 (green) and antigen (red) were compared over time. Scale bars – 3 μm. Data are representative of 3 independent experiments. (<bold>C</bold>) Representative TIRF images of WT and <italic>Itsn2<sup>-/-</sup></italic> B cells spread on anti-kappa coated glass coverslips and stained with fluorescently-labelled phalloidin. Scale bars – 3 µm. The quantification of spreading area and number of detected actin foci are shown graphically. Each dot represents an individual cell. Data are representative of 3 independent experiments where &gt; 100 cells of each genotype were analysed. (<bold>D</bold>) WT and <italic>Itsn2<sup>-/-</sup></italic> B cells were stimulated with 2 µg mL<sup>−1</sup> anti-IgM F(ab’)2 for 0, 2 or 5 min, and phosphorylation of Src, CD19, Akt (S473) and ERK were detected by Western blotting. Graphs next to each lane indicate the relative intensity of each band relative to ERK at t0. (<bold>E</bold>) Intracellular calcium influx in purified WT or <italic>Itsn2<sup>-/-</sup></italic> B cells after stimulation with 5 µg mL<sup>−1</sup> anti-kappa. (<bold>F</bold>) Naïve purified WT and <italic>Itsn2<sup>-/-</sup></italic> B cells were cultured in the presence of IL-4 alone or IL-4 and anti-IgM for 24 hr, and phosphorylation ERK and SHP1 measured by Western Blot. Student’s t-test, ns p&gt;0.05, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig5-v1"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26556.011</object-id><label>Figure 5—figure supplement 1.</label><caption><title>ITSN2 participates in the BCR signalling cascade.</title><p>(<bold>A</bold>) ITSN2 was ablated in A20 cells expressing a HEL-specific BCR by CRISPR-Cas9 mutagenesis. Representative TIRF images of WT and <italic>Itsn2<sup>-/-</sup></italic> (two independent clones) A20 cells without (upper row) or after transfection with GFP-ITSN2-L (lower row) spread on anti-kappa coated glass coverslips and stained with fluorescently-labelled phalloidin. Scale bars – 5 µm. The quantification of spreading area and number of detected actin foci are shown graphically. Each dot represents an individual cell. Data are representative of 2 independent experiments where &gt; 40 cells of each group were analysed. (<bold>B</bold>) Single-particle tracking (SPT) of CD19, IgM and IgD on WT or <italic>Itsn2<sup>-/-</sup></italic> B cells settled on nonstimulatory coverslips. Shown is the diffusion coefficient (<bold>D</bold>) in µm<sup>2</sup>/s. The median of 300 representative cells is given as value and indicated by red bars. 1,000–2000 tracks were analysed with a minimum of 20 cells from two experiments.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig5-figsupp1-v1"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26556.012</object-id><label>Figure 5—figure supplement 2.</label><caption><title>B cell activation ex vivo in response to BCR or TLR signals is not impaired in <italic>Itsn2<sup>-/-</sup> </italic>B cells.</title><p>(<bold>A</bold>) Naïve purified WT and <italic>Itsn2<sup>-/-</sup></italic> B cells were cultured in the presence of CD40L (0.5 µg.mL<sup>−1</sup>) or anti-Kappa (1 µg.mL<sup>−1</sup>) for 3 days, and percentage of live cells measure daily. (<bold>B–D</bold>) CTV-labelled WT and <italic>Itsn2<sup>-/-</sup></italic> B cells were cultured with anti-IgM (<bold>B</bold>), CD40L, CpG or LPS at the concentrations indicated on the graphs in presence (<bold>D</bold>) or absence (<bold>C</bold>) of IL-4 and IL-5. Proliferation profiles were analysed by flow cytometry after 3 (<bold>D</bold>) or 4 (<bold>C</bold>) days of culture. (<bold>E</bold>) CTV-labelled WT and <italic>Itsn2<sup>-/-</sup></italic> B cells we loaded with particles coated with IgM and CpG, and proliferation measured after 3 days of culture.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig5-figsupp2-v1"/></fig></fig-group><p>To test whether ITSN2 was recruited to the active sites of BCR signalling, we transfected A20 cells carrying a HEL-specific transgenic BCR (with the specificity of D1.3) with a construct expressing ITSN2L-GFP. These cells were allowed to settle onto planar lipid bilayers loaded with Alexa Fluor 633-labeled HEL, mimicking B cell interaction with APCs, and imaged by TIRF microscopy. Interestingly, as the cells spread over the bilayers and formed antigen microclusters, we observed the appearance of distinct ITSN2 foci in close proximity to antigen (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). However, we did not detect a direct colocalisation between ITSN2 and antigen microclusters. These results indicate that the role exerted by ITSN2 in immunity is independent of its physical recruitment to antigen microclusters, and instead may be through its ability to signal downstream effectors.</p><p>Given the early ITSN2 recruitment, we wanted to establish whether its absence influences the re-organisation of the actin cytoskeleton after BCR activation. WT and <italic>Itsn2<sup>-/-</sup></italic> B cells were allowed to spread on coverslips coated with immobilised antigen and stained for F-actin with phalloidin. WT B cells spread over the antigen-coated surface and exhibited a typical F-actin distribution, with a characteristic ring at the periphery of the cells, and about 14 actin foci per WT cell (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Although the overall spreading area was not affected in <italic>Itsn2<sup>-/-</sup></italic> B cells, the organisation of the F-actin network was altered (<xref ref-type="fig" rid="fig5">Figure 5C</xref>) as evident by a dramatic reduction in these foci with an average of 4 F-actin foci per cell. This is reminiscent of what has been previously reported for other components of the Wiskott-Aldrich syndrome protein complex (<xref ref-type="bibr" rid="bib28">Keppler et al., 2015</xref>; <xref ref-type="bibr" rid="bib31">Kumari et al., 2015</xref>) (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). We also observed a reduction in actin foci in two independent CRISPR/Cas9 inactivated <italic>Itsn2<sup>-/-</sup></italic> A20 lymphoma B cell lines expressing a HEL-specific BCR (<xref ref-type="bibr" rid="bib49">Ran et al., 2013</xref>). In these cell lines, actin foci formation was restored by overexpression of ITSN2LGFP, indicating that this defect is indeed due to ITSN2 deficiency (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>).</p><p>To determine whether this defect in actin cytoskeleton might reflect impaired BCR signalling, we stimulated WT and <italic>Itsn2<sup>-/-</sup></italic> B cells anti-IgM F(ab’)2 for 0, 2 or 5 min and measured the phosphorylation status of several canonical effectors by Western blotting. Both WT and <italic>Itsn2<sup>-/-</sup></italic> B cells exhibited a robust phosphorylation of the mitogen-activated protein kinase (MAPK) ERK upon BCR engagement (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). However, phosphorylation of Src, Akt and CD19 was reduced by at least 2-fold in <italic>Itsn2<sup>-/-</sup></italic> B cells compared to WT (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). This suggests that ITSN2 is implicated in propagating BCR-driven signals, in particular those leading to activation of the PI3K pathway. However, these early defects did not impair calcium influx, as both WT and <italic>Itsn2<sup>-/-</sup></italic> B cells exhibited robust calcium flux upon BCR engagement (<xref ref-type="fig" rid="fig5">Figure 5E</xref>).</p><p>We recently described that WIP-deficient B cells exhibit strong defects in activation of the PI3K pathway, in particular in CD19 phosphorylation, coupled to impaired actin foci formation (<xref ref-type="bibr" rid="bib28">Keppler et al., 2015</xref>). These defects are coupled to an increase in BCR and CD19 motility at the single molecule level. Measuring the diffusion coefficients of IgM, IgD and CD19 in <italic>Itsn2<sup>-/-</sup></italic> B cells, we observed a small increase in CD19 mobility, but much less marked than in the case of the WIP KO (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>).</p><p>To evaluate the consequence of impaired early BCR signalling in <italic>Itsn2<sup>-/-</sup></italic> B cells on distal signalling events, we cultured WT and <italic>Itsn2<sup>-/-</sup></italic> B cells in the presence of IL-4 with or without anti-IgM F(ab’)2. After 24 hr, cells were recovered and the phosphorylation of effector proteins was detected by Western blotting. Notably, in the condition where anti-IgM was added, we observed a consistent 40% reduction in levels of phosphorylated SHP1 in <italic>Itsn2<sup>-/-</sup></italic> B cells compared to their WT counterparts (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). In contrast pERK levels were not affected by ITSN2 deletion. This shows that indeed, ITSN2 deficiency leads to sustained signalling defects upon BCR engagement.</p><p>To gain insight into the physiological consequences of impaired signalling on B cell survival and activation, we measured the survival of cultured naïve WT and <italic>Itsn2<sup>-/-</sup></italic> B cells after BCR cross-linking. The results of this experiment revealed that cell survival was comparable in both cell types (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>, left panel). Moreover, when IL-4 and IL-5 were added to the culture medium, both WT and <italic>Itsn2<sup>-/-</sup></italic> B cells underwent robust proliferation as highlighted by the multiple peaks of CTV dilution (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>), indicating that in spite of their signalling impairment, <italic>Itsn2<sup>-/-</sup></italic> B cells can be activated ex vivo. Next we compared the activation of WT and <italic>Itsn2<sup>-/-</sup></italic> B cells in response to stimulation through TLR4, TLR9 or CD40, and found that in all tested conditions, both cell types proliferated to the same extent (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2C and D</xref>). To evaluate the role of ITSN2 in integrating BCR and TLR9 signals, we stimulated naïve WT and <italic>Itsn2<sup>-/-</sup></italic> B cells with particles coated with IgM and CpG, and measured proliferation after 3 days. We observed comparable proliferation patterns for WT and <italic>Itsn2<sup>-/-</sup></italic> B cells (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2E</xref>). These results indicate that ITSN2 deletion does not compromise B cell proliferation ex vivo in response to a range of soluble stimuli. Together, these results indicate that although ITSN2 deletion alters the actin cytoskeleton and PI3K signalling upon BCR stimulation, it does not seem to compromise B cell survival and proliferation in response to a range of soluble stimuli ex vivo.</p></sec><sec id="s2-6"><title><italic>Itsn2<sup>-/-</sup></italic> B cells are impaired in harnessing T cell help in vivo</title><p>Antigen binding to the BCR triggers its internalisation, processing and presentation on MHCII (<xref ref-type="bibr" rid="bib1">Amigorena et al., 1994</xref>). This allows antigen-primed B cells to interact with cognate CD4 T cells that provide them co-stimulatory signals required for their full activation (<xref ref-type="bibr" rid="bib33">Lanzavecchia, 1985</xref>). We first carried out a series of ex vivo assays in which we tested the effectiveness of <italic>Itsn2<sup>-/-</sup></italic> B cells in harnessing T cell help. We first measured internalisation of soluble and particulate antigen, and found similar rates for WT and <italic>Itsn2<sup>-/-</sup></italic> B cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref>). Next, we stimulated cells with particles coated with anti-IgM and Eα peptide to follow antigen presentation (<xref ref-type="bibr" rid="bib51">Rudensky AYu et al., 1991</xref>), and detected comparable levels of MHCII-Eα conjugates on both cell types after 5 hr (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>). Finally, we stimulated WT and <italic>Itsn2<sup>-/-</sup></italic> B cells with microspheres coated with anti-IgM antibodies and OVA, and co-cultured them with OTII T cells (<xref ref-type="bibr" rid="bib2">Barnden et al., 1998</xref>). We detected similar expression of activation markers (CD40, CD69 and CD86) by cells from both genotypes 24 and 48 hr after stimulation, and B and T cells proliferated with comparable rates (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D and E</xref>). These results indicate that ITSN2 is not required for BCR-driven antigen internalisation or for antigen presentation, and that <italic>Itsn2<sup>-/-</sup></italic> B cells can activate cognate T cells and sense costimulation ex vivo.</p><p>These ex vivo results do not reflect the significant germinal centre and antibody phenotype observed in <italic>Itsn2<sup>-/-</sup></italic> animals in vivo. There are some parallels to this, for example in the case of CD84 deficiency, that severely impairs humoral responses in vivo, but not T cell proliferation and activation ex vivo (<xref ref-type="bibr" rid="bib6">Cannons et al., 2010</xref>). Animals lacking the SLAM associated protein (SAP) also present with drastic in vivo defects that do not correlate with marked defects in T cell activation in vitro (<xref ref-type="bibr" rid="bib7">Cannons et al., 2006</xref>; <xref ref-type="bibr" rid="bib48">Qi et al., 2008</xref>). Therefore, we sought to analyse some aspects of the activation of <italic>Itsn2<sup>-/-</sup></italic> B cells in vivo. To this end, we crossed <italic>Itsn2<sup>-/-</sup></italic> mice to MD4-Tg expressing a BCR with high affinity to HEL (<xref ref-type="bibr" rid="bib20">Goodnow et al., 1988</xref>), thereafter referred to as HEL-<italic>Itsn2<sup>-/-</sup></italic>). We next purified HEL-WT and HEL-<italic>Itsn2<sup>-/-</sup></italic> B cells, labelled them with CTV, and transferred them to C57BL/6 CD45.1 recipients together with CFSE-labelled OTII T cells. Following adoptive transfer, we immunised mice hosts with HEL and OVA coated microspheres and analysed their spleens by flow cytometry 3 days later. Under these conditions, WT B cells underwent intense proliferation, as highlighted by the multiple peaks of CTV dilution. Strikingly, <italic>Itsn2<sup>-/-</sup></italic> B cells proliferated to a lesser extent than WT cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>), indicating that ITSN2 deletion compromises B cell activation in vivo.</p><fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.26556.013</object-id><label>Figure 6.</label><caption><title>ITSN2 is required for B cell activation in vivo.</title><p>(<bold>A</bold>) CTV-labelled HEL-WT or HEL-<italic>Itsn2<sup>-/-</sup></italic> B cells and CFSE-labelled OTII T cells were transferred to CD45.1 hosts, subsequently immunised with HEL and OVA coated microspheres. Proliferation of both cell types was measured by flow cytometry 3 days after immunisation. Data are representative of 4 independent experiments with 3–6 animals in each group. (<bold>B</bold>) CTV-labelled HEL-WT and CFSE-labelled HEL-<italic>Itsn2<sup>-/-</sup></italic> B cells were transferred to WT recipients prior to intravenous immunisation with beads coated with HEL and Eα peptide. Expression of MHCII-Eαconjugates (quantified on the right as the geometric mean of the MHCII- Eα fluorescence signal) by both cell types was measured 24 hr after immunisation. Data are representative of 2 independent experiments with 5–10 mice. (<bold>C–F</bold>) CFSE-labelled HEL-WT and CTV-labelled HEL-<italic>Itsn2<sup>-/-</sup></italic> B cells were transferred to CD45.1 hosts, and immunised with HEL and OVA coated microspheres. Expression of CD84 (<bold>C</bold>), SLAM (<bold>C</bold>), ICOSL (<bold>C</bold>), CD86 (<bold>D</bold>), CD40 (<bold>D</bold>) and MHCII (<bold>D</bold>) was measured by flow cytometry 24 hr after immunisation. Data are representative of 3 independent experiments with 5–10 mice. (<bold>E–F</bold>) WT and <italic>Itsn2<sup>-/-</sup></italic> littermates were immunised with NP-KLH precipitated in Alum, and spleens analysed by flow cytometry 13 days after immunisation. Expression of CD84 (<bold>E</bold>), SLAM (<bold>E</bold>), ICOSL (<bold>E</bold>), Ly108 (<bold>F</bold>), CD40 (<bold>F</bold>) and MHCII (<bold>F</bold>) on germinal centre B cells was measured. Data are representative of 3 independent experiments with 5–10 mice in each group. Paired t-test (<bold>B, C, D</bold>) or Student’s t-test (<bold>E,F</bold>), ns p&gt;0.05, *p&lt;0.05, ***p&lt;0.001, ****p&lt;0.0001.</p></caption><graphic mime-subtype="postscript" mimetype="application" xlink:href="elife-26556-fig6-v1"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.26556.014</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Antigen uptake and reception of T cell help ex vivois not impaired in <italic>Itsn2-/- </italic>B cells.</title><p>(<bold>A–B</bold>) Purified naïve WT or <italic>Itsn2<sup>-/-</sup></italic> B cells were labelled on ice with soluble biotinylated anti-IgM (<bold>A</bold>) or anti-IgM coated particles (<bold>B</bold>), and incubated at 37°C for the indicated times, prior to fixation. Extracellular antigen was then detected by flow cytometry. Data are quantified on the right panel as percentage of initial MFI for each sample (<bold>A</bold>), or the percentage of the cells with external beads (<bold>B</bold>). Data are representative of more than 3 independent experiments with 2 mice in each group. (<bold>C</bold>) Purified naïve WT or <italic>Itsn2<sup>-/-</sup></italic> B cells were stimulated with beads coated with anti-IgM and Eα peptide, and expression of MHCII-Eα conjugates measured by flow cytometry 5 hr after stimulation. Data are quantified on the right panel and show the Eα presentation for increasing amounts of Eα on the beads. (<bold>D–E</bold>) CTV-labelled WT or <italic>Itsn2<sup>-/-</sup></italic> B cells were stimulated with beads coated with IgM and OVA, and co-cultured with CFSE-labelled OTII T cells. Expression of CD40, CD86 and CD69 was measured by flow cytometry at d1 and d2 (<bold>D</bold>). B and T cell proliferation rates according were characterised to CFSE and CTV dilution at d3 of the culture (<bold>E</bold>). (<bold>F</bold>) CFSE-labelled WT and CTV-labelled <italic>Itsn2<sup>-/-</sup></italic> MD4 B cells were transferred adoptively into WT recipients, and after 24 hr, animals were injected i.v. with fluorescently-labelled HEL-coated particles. Beads internalisation was measured by flow cytometry 24 hr post-injection.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig6-figsupp1-v1"/></fig></fig-group><p>To test whether the impaired activation of <italic>Itsn2<sup>-/-</sup></italic> B cells derived from defects in antigen uptake or presentation in vivo, we transferred CTV-labelled HEL-WT and CFSE-labelled HEL-<italic>Itsn2<sup>-/-</sup></italic> B cells to WT recipients prior to immunisation with fluorescent beads coated with HEL and Eα. We found similar numbers of WT and <italic>Itsn2<sup>-/-</sup></italic> B cells positive for beads, suggesting that ITSN2 is not required for antigen uptake in vivo (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1F</xref>). Next, we measured presentation of Eα peptide on MHCII by flow cytometry 20 hr after antigenic challenge in vivo. In these conditions, beads-positive WT and <italic>Itsn2<sup>-/-</sup></italic> B cells expressed comparable amounts of MHCII- Eα conjugates (<xref ref-type="fig" rid="fig6">Figure 6B</xref>), indicating that ITSN2 is not required for antigen capture and presentation in vivo.</p><p>We next measured the expression of various surface receptors on activated B cells 20 hr after immunisation. Strikingly, we found that the expression of the immune receptors CD84 and SLAM, and of the inducible co-stimulator ligand (ICOSL) were significantly decreased in <italic>Itsn2<sup>-/-</sup></italic> B cells compared to WT levels (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Both cell types expressed similar levels of the co-stimulatory molecules CD40 and CD86, as well as MHCII (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). This shows that ITSN2 is required for the upregulation of several surface receptors after antigen challenge in vivo.</p><p>To determine whether similar discrepancies could be observed at later stages during the immune response, we immunised WT and <italic>Itsn2<sup>-/-</sup></italic> animals with NP-KLH in alum and measured the expression of various markers by GC B cells after 13 days. Interestingly, <italic>Itsn2<sup>-/-</sup></italic> GC B cells expressed reduced levels of CD84, SLAM, and ICOS-L compared to their WT counterparts (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). In contrast, expression of the costimulatory receptor CD40, the negative regulator Ly108 and MHCII were comparable in WT and <italic>Itsn2<sup>-/-</sup></italic> B cells (<xref ref-type="fig" rid="fig6">Figure 6F</xref>).</p><p>This set of experimental results suggests deletion of ITSN2 leads to alterations in the expression of various receptors upregulated upon B cell activation in vivo, which were maintained when the cells progressed into the GC reaction. A common feature of the receptors whose expression is deregulated in <italic>Itsn2<sup>-/-</sup></italic> B cells is their involvement in mediating interactions between B cells and cognate T cells (<xref ref-type="bibr" rid="bib12">Crotty, 2015</xref>). ICOSL binds to ICOS expressed on CD4 T cells, and participates in instructing T cells to differentiate into Tfh cells (<xref ref-type="bibr" rid="bib37">Liu et al., 2015</xref>); while CD84 and SLAM are expressed by both B and T cells and can engage into homotypic interactions, thus participating to the establishment of B-T synapses (<xref ref-type="bibr" rid="bib56">Schwartzberg et al., 2009</xref>). Notably, SAP-deficient T cells also present with altered expression of surface receptors, with markedly reduced ICOS expression upon stimulation (<xref ref-type="bibr" rid="bib7">Cannons et al., 2006</xref>). This correlates with shortened contacts with B cells in vivo (<xref ref-type="bibr" rid="bib48">Qi et al., 2008</xref>). These observations prompted us to further characterise the function of ITSN2, in the context of cognate B-T interactions in vivo.</p></sec><sec id="s2-7"><title>ITSN2 is required for the establishment of long-term interactions between B and T cells</title><p>To study the impact of ITSN2 deficiency on B cell behaviour in vivo, CFSE-labelled WT and CTV-labelled <italic>Itsn2<sup>-/-</sup></italic> B cells were transferred to WT recipients. After 24 hr, popliteal and inguinal lymph nodes were explanted and imaged by multiphoton microscopy. We observed that both cell types were found in B cell follicles in comparable proportions, they moved at an average speed of 5 µm min<sup>−1</sup>, and exhibited the typical random-walk behaviour described for naïve B cells (<xref ref-type="bibr" rid="bib42">Miller et al., 2002</xref>) (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>, and <xref ref-type="video" rid="fig7video1">Figure 7—video 1</xref>). This indicates that <italic>Itsn2<sup>-/-</sup></italic> B cells are able to home to skin draining lymph nodes as efficiently as WT B cells and that ITSN2 is not required for B cell motility in steady-state conditions.</p><fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.26556.015</object-id><label>Figure 7.</label><caption><title><italic>Itsn2<sup>-/-</sup></italic> B cells are impaired in forming long-term conjugates with T cells.</title><p>(<bold>A–B</bold>) CTV-labelled HEL-WT and CFSE-labelled-<italic>Itsn2<sup>-/-</sup></italic> B cells were transferred to WT recipients, and explanted popliteal lymph nodes were imaged with a multiphoton microscope 24 hr after adoptive transfer. A representative field of view as well as the associated tracks are shown. (<bold>B</bold>) Quantification representing the average speed and the straightness of the tracks. Data are representative of 2 independent experiments where 4–6 lymph nodes were imaged. Student-s t-test, n.s. p&gt;0.05, *p&lt;0.05. (<bold>C–E</bold>) CTV-labelled HEL-WT and CFSE-labelled HEL-<italic>Itsn2<sup>-/-</sup></italic> B cells were transferred to WT recipients together with unlabelled (<bold>C</bold>) or SNARF-1-labelled (<bold>D–E</bold>) OTII T cells prior to intra-footpad immunisation with HEL and OVA coated microspheres. Popliteal lymph nodes were explanted 18–20 hr later imaged by confocal (<bold>C</bold>) or multiphoton microscopy (<bold>D–E</bold>). (<bold>C</bold>) Frozen sections were stained with antibodies against B220 and TCRβ to distinguish B and T cell areas. Quantified data on the right indicate the distance from each WT (red) or <italic>Itsn2<sup>-/-</sup></italic> (green) B cell to the edge of the LN. Scale bars – 200 µm. Paired t-test, n.s. – p&gt;0.05). (<bold>D</bold>) Representative images of a whole popliteal lymph node as well as higher magnification images showing typical interactions between WT B cells (cyan), <italic>Itsn2<sup>-/-</sup></italic> B cells (green) and OTII T cells (red). Dotted lines were added for illustrative purposes and indicate the localisation of two B cell follicles. (Scale bar – 80 µm on the low magnification and 10 µm on the higher magnification.) (<bold>E</bold>) Quantification of the overall length of B-T interactions (left panel) and the fraction of interactions shorter (middle panel) or longer (right panel) than 25 min. Data were pooled from 3 independent experiments where 2–3 lymph nodes were imaged. Student’s t-test, ns p&gt;0.05, *p&lt;0.05, **p&lt;0.01.</p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-26556-fig7-v1"/></fig><media id="fig7video1" mime-subtype="mp4" mimetype="video" xlink:href="elife-26556-fig7-video1.mp4"><object-id pub-id-type="doi">10.7554/eLife.26556.016</object-id><label>Figure 7—video 1.</label><caption><title>Representative movie of part of a popliteal lymph node, showing homeostatic migration of WT (gray) and <italic>Itsn2<sup>-/-</sup></italic> (green) B cells.</title></caption></media><media id="fig7video2" mime-subtype="mp4" mimetype="video" xlink:href="elife-26556-fig7-video2.mp4"><object-id pub-id-type="doi">10.7554/eLife.26556.017</object-id><label>Figure 7—video 2.</label><caption><title>Representative movie of part of a popliteal lymph node, showing long term interaction between a WT B cell (cyan) and OTII T cells (red), and shorter conjugates between <italic>Itsn2<sup>-/-</sup></italic> B cells (green) and OTII T cells (red).</title></caption></media></fig-group><p>Upon binding to cognate antigen, B cells adopt a different behaviour, and migrate towards the B-T border where encounter with CD4 T cells is more likely. To test whether ITSN2 was involved for B cell relocalisation upon activation, we transferred CTV-labelled HEL-WT, and CFSE-labelled HEL-<italic>Itsn2<sup>-/-</sup></italic> to WT recipients. After 24 hr, some animals were immunised with microspheres coated with HEL and OVA via intra-footpad injections, while others received PBS injections as a control. We explanted popliteal lymph nodes 20 hr after immunisation and used them to prepare cryosections, which were stained with antibodies against B220 and TCRβand imaged with a confocal microscope. Using this method, we were able to analyse the localisation of WT and <italic>Itsn2<sup>-/-</sup></italic>B cells within the LN before and after immunisation. In naïve recipients, both cell types were found predominantly within B cell follicles (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). As expected, immunisation with cognate antigen triggered the displacement of B cells towards the B-T border with <italic>Itsn2<sup>-/-</sup></italic> B cells phenocopying the WT, indicating that ITSN2 is not required for B cell relocalisation upon activation (<xref ref-type="fig" rid="fig7">Figure 7C</xref>).</p><p>To characterise cognate interactions between activated T and B cells in vivo, we transferred labelled HEL-WT, HEL-<italic>Itsn2<sup>-/-</sup></italic> and OTII T cells to WT recipients prior to intra-footpad immunisation with microspheres coated with HEL and OVA. 18 hr after immunisation, we explanted the draining popliteal lymph nodes and imaged them with a multiphoton microscope to visualise the formation of B–T conjugates. WT B cells formed conjugates with OTII T cells, many of which were stable and lasted for longer than 25 min (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref> and <xref ref-type="video" rid="fig7video2">Figure 7—video 2</xref>). In contrast, although <italic>Itsn2<sup>-/-</sup></italic> B cells did form conjugates with OTII T cells, the average length of interaction was reduced compared to those of WT B cells. Moreover, we observed a significant decrease in the fraction of <italic>Itsn2<sup>-/-</sup></italic> B cells that interact with T cells for longer than 25 min (<xref ref-type="fig" rid="fig7">Figure 7D and E</xref> and <xref ref-type="video" rid="fig7video2">Figure 7—video 2</xref>). These results show that ITSN2 expression in B cells is essential for the formation of long-lived cognate B–T conjugates.</p><p>Together, this study highlights the role of ITSN2 in the differentiation of GC B cells and the production of high affinity antibodies upon immunisation. The molecular mechanism for this resides in the fact that <italic>Itsn2<sup>-/-</sup></italic> B cells fail to upregulate several receptors upon activation, which severely compromises their ability to form stable conjugates with cognate T cells, and hence their full activation and entry into germinal centres.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, through a combination of immunisation and infection experiments in mice lacking ITSN2, we have provided the first analysis of the role of this adaptor protein during immune responses. ITSN2 deficiency hindered early signalling downstream of BCR engagement and cytoskeleton remodelling triggered by antigen recognition, but did not compromise B cell activation ex vivo. However, ITSN2 deletion in B cells in vivo resulted in mice with severely impaired formation of GC B cells, reduced antibody responses and incomplete protection after Flu vaccination. Furthermore, in vivo, activation of <italic>Itsn2<sup>-/-</sup></italic> B cells was impaired, and the cells expressed reduced amounts of surface receptors involved in mediating interactions between B and T cells. As a consequence, ITSN2 deficiency in B cells impaired the establishment of long term conjugates with cognate T cells.</p><p>The characterisation of the adaptive immune response during viral infection or immunisation highlighted that ITSN2 deletion causes severe defects in the differentiation of GC B cells and production of high affinity antibodies. These results are in line with the role of ITSN2-interaction partners WIP, WASp, and N-WASP in B cell function; indeed, B cells lacking WIP or both WASp and N-WASp are also impaired in entering the GC reaction and producing antibodies after vaccination (<xref ref-type="bibr" rid="bib28">Keppler et al., 2015</xref>; <xref ref-type="bibr" rid="bib66">Westerberg et al., 2012</xref>). Similarly, ablation of DOCK8, another multimodular adaptor with GEF activity, in the B cell compartment causes defects in the generation of long term antibody responses (<xref ref-type="bibr" rid="bib50">Randall et al., 2009</xref>; <xref ref-type="bibr" rid="bib52">Ruusala and Aspenström, 2004</xref>). Notably, mutations in <italic>WAS</italic>, WIPF1 or DOCK8 have been reported in human immunodeficiencies (<xref ref-type="bibr" rid="bib59">Sullivan et al., 1994</xref>; <xref ref-type="bibr" rid="bib68">Zhang et al., 2009</xref>), underscoring the importance of these cytoskeleton regulators during immune responses. Interestingly, ITSN2 has been identified as a potential candidate for primary immunodeficiency in a bioinformatics screen (<xref ref-type="bibr" rid="bib27">Keerthikumar et al., 2009</xref>). Moreover, ITSN2 was found to be overexpressed in B lymphocytes from patients with Sjögren’s syndrome (<xref ref-type="bibr" rid="bib36">Lessard et al., 2013</xref>; <xref ref-type="bibr" rid="bib41">Miceli-Richard et al., 2016</xref>).</p><p>The BCR engagement of membrane-tethered ligands leads to the formation of antigen microclusters and triggers a complex signalling cascade (<xref ref-type="bibr" rid="bib32">Kurosaki et al., 2010</xref>). Here, we found that ITSN2 is recruited to the plasma membrane upon BCR engagement, and although it is not directly recruited to antigen microclusters, both ITSN2 isoforms were rapidly phosphorylated on tyrosine residues after antigen binding to the BCR. In various cell lines, ITSN2 phosphorylation has been reported in response to stimulation by estrogen growth factor (<xref ref-type="bibr" rid="bib46">Novokhatska et al., 2013</xref>). Antigen engagement by the BCR leads to the activation of the Src family kinases and Syk, leading to tyrosine phosphorylation of multiple effectors, including Igα and Igβ (<xref ref-type="bibr" rid="bib32">Kurosaki et al., 2010</xref>). This promotes the recruitment of proteins containing Src homology (SH2) domains that play a central role in propagating BCR signalling (<xref ref-type="bibr" rid="bib15">Dal Porto et al., 2004</xref>). Interestingly, ITSN2 was found to interact with the SH2 domains of multiple proteins, such as Fyn, Grb2 or else PLCγ2 (<xref ref-type="bibr" rid="bib46">Novokhatska et al., 2013</xref>). However, the precise functional consequences of ITSN2 phosphorylation in the context of BCR stimulation are still to be investigated in detail.</p><p><italic>Itsn2<sup>-/-</sup></italic> B cells were selectively impaired in forming actin foci in response to BCR signalling. Interestingly, WIP deficiency in B cells also compromises the appearance of these actin nodes (<xref ref-type="bibr" rid="bib28">Keppler et al., 2015</xref>). In T cells, similar actin-rich structures have been proposed to be sites of WASp-dependent actin polymerisation, to participate in PLCγ1 activation, and were missing in T cells deficient in WASp and N-WASp (<xref ref-type="bibr" rid="bib31">Kumari et al., 2015</xref>). Thus, the similarity of the defects in actin morphology caused by deletion of ITSN2, WIP and WASp interrogates whether these proteins participate in the same signalling axis to regulate actin remodelling after antigen engagement of the BCR. Such interconnection has been reported in the context of Vaccinia virus infection, during which ITSN1, the other member of the intersectin family, was reported to collaborate with Nck and Cdc42 to promote N-WASp dependent actin polymerisation (<xref ref-type="bibr" rid="bib25">Humphries et al., 2014</xref>).</p><p>Antigen binding to the BCR leads to antigen internalization into endosomal compartments, trafficking of the internalized antigen to lysosomes for proteolytic cleavage, loading of peptide antigens onto MHCII molecules, and subsequent presentation to cognate T cells (<xref ref-type="bibr" rid="bib1">Amigorena et al., 1994</xref>; <xref ref-type="bibr" rid="bib33">Lanzavecchia, 1985</xref>). We found that B cells lacking ITSN2 were as effective as WT cells in antigen internalization and presentation, indicating that ITSN2 is dispensable for these processes. In the context of T-dependent responses, antigen presentation by B cells is critical for the establishment of the Tfh population. Tfh cells are strictly required for the generation of high-affinity, class-switched antibodies and for the establishment of B cell memory (<xref ref-type="bibr" rid="bib64">Vinuesa and Cyster, 2011</xref>). Tfh differentiation and function relies on multiple signals, including contact-dependent interactions between TCR and MHCII-peptide conjugates, ICOS or CD28 and their respective ligands ICOS-L and CD80/CD86, and soluble signals derived from cytokines, such as IL21 or IL6 (<xref ref-type="bibr" rid="bib12">Crotty, 2015</xref>). Notably, animals deficient for ITSN2 show reduced numbers of B cells engaged in the GC reaction, but comparable or increased numbers of Tfh cells. This may be due to the fact that antigen presentation is not defective in <italic>Itsn2<sup>-/-</sup></italic> B cells.</p><p>Interactions between GC B cells and Tfh cells occur predominantly in the GC light zone, and are key for the affinity-based selection of GC B cells. Hypermutated GC B cells with higher affinity capture more antigen from FDCs than lower affinity variants, present more MHCII-peptide conjugates, and form longer interactions with cognate Tfh cells (<xref ref-type="bibr" rid="bib57">Shulman et al., 2013</xref>). As a result, they receive stronger signals and have a proliferative advantage after re-entering the dark zone (<xref ref-type="bibr" rid="bib19">Gitlin et al., 2014</xref>). In <italic>Itsn2<sup>-/-</sup></italic> mice, the GC cells were biased to the dark zone, with fewer cells exhibiting the light zone markers. This may be explained by defects <italic>Itsn2<sup>-/-</sup></italic> B cells presented in establishing long-term interactions with cognate T cells.</p><p>ITSN2 deficiency in B cells was associated with reduced length of cognate B-T interactions. In mouse, SAP deletion dramatically impairs antibody responses, as SAP KO T cells fail to establish long term contacts with cognate B cells, and are not retained in the GC (<xref ref-type="bibr" rid="bib11">Crotty et al., 2003</xref>; <xref ref-type="bibr" rid="bib48">Qi et al., 2008</xref>). SAP is a small adaptor protein mediating signals downstream of receptors of the SLAM family, such as CD84, SLAM or Ly108. T cell intrinsic deficiency in CD84, but not in SLAM or Ly108, is associated to reduced GC formation and to shortened interactions between B and T cells, but without recapitulating the phenotype of SAP inactivation (<xref ref-type="bibr" rid="bib6">Cannons et al., 2010</xref>; <xref ref-type="bibr" rid="bib7">2006</xref>; <xref ref-type="bibr" rid="bib26">Kageyama et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">McCausland et al., 2007</xref>).</p><p>The deletion of ITSN2 severely impaired B cell activation in vivo and was associated to decreased expression of various surface receptors both shortly after immunisation and on GC B cells. These results intriguingly mirrors the correlation observed in SAP-deficient T cells between decreased ICOS expression, and impaired formation of B-T conjugates (<xref ref-type="bibr" rid="bib7">Cannons et al., 2006</xref>; <xref ref-type="bibr" rid="bib48">Qi et al., 2008</xref>). In particular, <italic>Itsn2<sup>-/-</sup></italic> B cells displayed reduced levels of SLAM and CD84, two receptors of the SLAM family, and of ICOSL. This is particularly relevant, since IL4 production by Tfh cells is SLAM dependent (<xref ref-type="bibr" rid="bib67">Yusuf et al., 2010</xref>), while that of IL21 is dependent on ICOS triggering (<xref ref-type="bibr" rid="bib44">Morita et al., 2011</xref>). The reduced expression of these molecules by in ITSN2 GC B cells could result in reduced cytokine secretion by Tfh cells, and hence hinder their reception of T cell help.</p><p>In contrast, expression of Ly108, another member of the SLAM family, was unaffected by ITSN2 deletion. CD84, SLAM and Ly108 are upregulated by B cells upon activation (<xref ref-type="bibr" rid="bib6">Cannons et al., 2010</xref>). They can all signal through the intracellular adaptor SAP, and function by engaging into homotypic interactions (<xref ref-type="bibr" rid="bib35">Latour et al., 2001</xref>). Interestingly, the singularity of Ly108 function is its ability to mediate a strong inhibitory signal, as deficiency in Ly108 is sufficient to alleviate the SAP requirement for the GC reaction (<xref ref-type="bibr" rid="bib26">Kageyama et al., 2012</xref>). <italic>Itsn2<sup>-/-</sup></italic> GC B cells express reduced levels of SLAM and CD84, but not of Ly108, which could alter the signalling mediated by these receptors, and hence the outcome of B-T interactions.</p><p>In summary, we have delineated a role for ITSN2, an interacting partner of Cdc42, WASp, and WIP, in generating optimal immune responses. We probed the function of this protein in the B cell compartment by studying ITSN2 deficient mice and mixed BM chimeras and using a combination of immunisation and infection experiments. Our results identify ITSN2 as a regulator of B cell activation, engagement into the GC reaction and cognate B-T interactions. They open new perspectives to understand the intricate regulatory network underlying cognate interactions between B and T cells.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type (species) <break/>or resource</th><th>Designation</th><th>Source or reference</th><th>Identifiers</th><th>Additional information</th></tr></thead><tbody><tr><td>Gene (<italic>Mus musculus</italic>)</td><td><italic>Itsn2</italic></td><td>NA</td><td>ENSMUSG00000020640; MGI:1338049</td><td/></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td valign="bottom"><italic>Itsn2<sup>-/-</sup></italic></td><td>KOMP consortium</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5631233">MGI:5631233</ext-link></td><td>Itsn2<sup>tm1.1(KOMP)Vlcg</sup></td></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td valign="bottom">µMT</td><td valign="bottom">doi:10.1038/350423a0</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_HAR:1682">IMSR_HAR:1682</ext-link></td><td>(beta)-globin (mu)MT<sup>-/-</sup></td></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td valign="bottom">MD4</td><td valign="bottom">doi:10.1038/334676a0</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5006966">MGI:5006966</ext-link></td><td>Tg(IghelMD4)4Ccg</td></tr><tr><td>Genetic reagent (<italic>M. musculus</italic>)</td><td valign="bottom">OTII</td><td valign="bottom">doi:10.1046/j.1440–1711.1998.00709.x</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:004194">IMSR_JAX:004194</ext-link></td><td>B6.Cg-Tg(TcraTcrb)425Cbn/J</td></tr><tr><td>Cell line (<italic>M. musculus</italic>)</td><td>A20 cells with HEL-specific D1.3 BCR</td><td valign="bottom">http://dx.doi.org/10.1016/S1074-7613(00)80580–4</td><td/><td/></tr><tr><td>Transfected construct (plasmid)</td><td>ITSN2L GFP</td><td>Michael Way</td><td/><td>pEGFP-C1 ITSN2L</td></tr><tr><td>Antibody (rabbit polyclonal)</td><td>anti-ITSN2 antibody</td><td>Novus</td><td>NBP1-71833; RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11038593">AB_11038593</ext-link></td><td>1:1000 in 5% Milk TBS-T</td></tr><tr><td>Sequence-based reagent</td><td>sgRNA1</td><td>this paper</td><td/><td>Forward - CACCGTAGCTATAGAGAACTCTTGC; Reverse - AAACGCAAGAGTTCTCTATAGCTAC</td></tr><tr><td>Sequence-based reagent</td><td>sgRNA 2</td><td>this paper</td><td/><td>Forward - CACCGGGGGTTGTTTCATGATAGGA; Reverse - AAACTCCTATCATGAAACAACCCCC</td></tr><tr><td>Peptide, recombinant protein</td><td>Eα peptide</td><td>The Francis Crick Institute peptide chemistry unit; doi:10.1038/353660a0</td><td/><td>Sequence: Biotin-GSGFAKFASFEAQGALANIAVDKA-COOH</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animal breeding and generation</title><p>ITSN2<sup>tm1.1Komp(Vlcg)</sup> (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5631233">MGI:5631233</ext-link>) animals, where ITSN2 expression is disrupted by the insertion of a LacZ cassette were obtained from the KOMP consortium (<xref ref-type="bibr" rid="bib58">Skarnes et al., 2011</xref>; <xref ref-type="bibr" rid="bib62">Valenzuela et al., 2003</xref>). They were crossed to mice expressing the hen egg lysozyme (HEL) specific MD4 B cell receptor (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/MGI:5006966">MGI:5006966</ext-link>, [<xref ref-type="bibr" rid="bib20">Goodnow et al., 1988</xref>]). OTII mice were used for purification of ovalbumin (OVA) restricted CD4 T cells (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_JAX:004194">IMSR_JAX:004194</ext-link>, [<xref ref-type="bibr" rid="bib2">Barnden et al., 1998</xref>]). For adoptive transfer experiments, congenic CD45.1 C57BL6 mice were obtained from the internal breeding facility at the Francis Crick Institute and µMT ([<xref ref-type="bibr" rid="bib29">Kitamura et al., 1991</xref>], RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/IMSR_HAR:1682">IMSR_HAR:1682</ext-link>, B cell deficient) mice were bred internally. C57BL6/J mice were either obtained internally or purchased from the Jackson Laboratory.</p><p>For the generation of mixed bone marrow chimeras, 6–8 week-old recipient mice were provided acidified water one week before the beginning of the procedure, lethally irradiated using 2 × 6 Gy, and intravenously injected 24 hr later with 2.10<sup>6</sup> donor bone marrow cells in adequate proportions. Animals were bled 8–10 weeks after adoptive transfer to check the reconstitution efficiency, and were subsequently used for experiments.</p><p>Mice were bred and maintained at the animal facility at the Francis Crick Institute. All experiments were approved by the Animal Ethics Committee of the Francis Crick Institute and the UK Home Office and by the Institutional Animal Care and Use Committee (IACUC) of the Massachusetts General Hospital. Animal experiments conducted at the Ragon Institute were performed in accordance with the regulations of the American Association for the Accreditation of Laboratory Animal Care (AAALAC).</p></sec><sec id="s4-2"><title>Cell isolation, labelling and culture</title><p>Splenic naive B or CD4 T lymphocytes were purified using negative B cell or CD4 T cell isolation kits yielding enriched populations of 95–98% (B cells) and 80% (T cells), respectively (Miltenyi Biotec, Germany). Purified B or T cells were labelled in PBS with 2 μM CTV (Life Technologies, Carlsbad, California), 2 μM SNARF1 (Invitrogen), or 1 μM CFSE (Life Technologies) for 5 min at 37°C and washed (twice in case of CFSE labelling) in complete B cell medium. Cells were maintained in complete B cell medium (RPMI supplemented with 10% FCS, 25 mM Hepes, Glutamax, penicillin streptomycin (Invitrogen), and 100 μM β-mercaptoethanol (Sigma-Aldrich, St. Louis, Missouri)).</p></sec><sec id="s4-3"><title>Cell lines and transient transfection</title><p>A20 lymphoma cells expressing HEL-specific D1.3 receptor (<xref ref-type="bibr" rid="bib4">Batista and Neuberger, 1998</xref>) generated in the laboratory were cultured in RPMI with 10% FCS, 25 mM HEPES, glutamax, penicillin streptomycin (Invitrogen) and 100 µM β-mercaptoethanol. Cells were transfected using Amaxa Nucleofactor Technology (KitV, programme L-013, Lonza, Switzerland) according to the manufacturer’s instructions. Mycoplasma contamination status was not tested. Transfected cells were used within 5–8 hr after transfection. Constructs encoding GFP-ITSN2-L were kindly provided by M.Way (The Francis Crick Institute).</p></sec><sec id="s4-4"><title>CRISPR/Cas9-mediated ITSN2 deletion</title><p>ITSN2 was deleted in A20 cells using the CRISPR/Cas9 system. Briefly, sgRNA targeting ITSN2 were cloned in the vectors expressing Cas9GFP (Adgene PX458); and the following targeting regions were used: CACCGTAGCTATAGAGAACTCTTGC and AAACGCAAGAGTTCTCTATAGCTAC (sgRNA1) or CACCGGGGGTTGTTTCATGATAGGA and AAACTCCTATCATGAAACAACCCCC (sgRNA2). The constructs were transiently expressed in derivatives of A20 B cell line expressing hen egg lysozyme (HEL)-specific D1.3 BCR for 12 hr followed by single-cell sorting of GFP-positive cells into 96-well plates. The cells were maintained in complete B cell medium. Single cell clones were expanded and screened for ITSN2 deletion by immunoblotting. Clones were matched to WT cells for receptor expression and clones obtained with both sgRNAs were retained for experiments.</p></sec><sec id="s4-5"><title>Immunisation, ELISA and ELISPOT</title><p>For immunization, mice were injected i.p. with 50 μg NP-KLH (Biosearch Technology, Novato, California) in 4 mg Alum (Thermo Fisher Scientific, Waltham, Massachussets). Blood samples were taken from the lateral tail vein on 0, 7, 14, 21, 28 days after immunization.</p><p>NP-specific antibody titres were detected by ELISA, using NP20-BSA or NP4-BSA for capture, and biotinylated anti–mouse IgM (Southern Biotech, Birmingham, Alabama), IgG (Southern Biotech), IgG2b (Southern Biotech), IgG2c (Southern Biotech), and IgG3 (BD, Franklin Lakes, New Jersey) for detection. Titres were determined from the dilution curve in the linear range of absorbance.</p><p>For detection of NP-specific antibody secreting cells, Multiscreen filter plates (Millipore, Burlington, Massachussets) were activated for 1 min with ethanol (Sigma Aldrich), washed with sterile PBS, and coated with 1 µg.mL<sup>−1</sup> NP20-BSA in PBS overnight at 4°C. After blocking in complete B cell medium, splenocytes collected from immunised mice were plated at various concentrations. Biotinylated anti-mouse IgM or IgG (Southern Biotech) were used for detection.</p><p>ELISA and ELISPOT plates were developed with alkaline-phosphatase streptavidin (Sigma-Aldrich) and phosphorylated nitrophenyl phosphate (ELISA, Sigma-Aldrich) or BCIP/NIST (ELISPOT, Sigma-Aldrich). Absorbance at 405 nm was determined with a SPECTRA-max190 plate reader (Molecular Devices, Sunnyvale, California). Imaging of ELISPOT plates was performed using an Immunospot analyser (Immunospot, Cleveland, Ohio).</p></sec><sec id="s4-6"><title>Infection</title><p>For infection, mice were intranasally immunized with 3.10<sup>4</sup> pfu of Influenza A virus (PR8 strain) or injected with 10<sup>4</sup> pfu of Vaccinia virus (Western Reserve) intra-footpad. For survival experiments, animals were weighed daily and sacrificed when exhibiting 20% wt loss. For Influenza vaccination, animals were immunised with hemagglutinin trimer (kindly provided by Daniel Lingwood) together with Sigma adjuvant by intravenous route, and 4 weeks later challenged with 1.5.10<sup>5</sup> pfu Influenza A PR8. Animals were weighed daily, and sacrificed when exhibiting 40% wt loss. In the case of infection with Vaccinia virus, immune responses in the draining lymph nodes were characterised 7 days after infection.</p></sec><sec id="s4-7"><title>Flow cytometry</title><p>Single cell suspensions were prepared from spleen, lymph nodes, bone marrow or peritoneal lavage. After blocking Fc receptors using anti CD16/32 antibodies, cells were stained with the appropriate combination of the following antibodies: B220 (RA3-6B2), TCRβ (H57-597), CD21 (7G6), CD4 (GK1.5), CD8 (53–6.7), CD3 (145–2 C11), CD23 (B3B4), CD24 (M1/69), CD43 (S7), Ly-51 (6C3), B and T cell activation antigen (GL7), CD95 (Jo2), CD138 (281.2), IgG1 (A85.1), CD5 (53–7.3), CD11b (M1/70), CD19 (1D3), IgM (1B4B1 or II/41), IgD (11-26), CXCR4 (2B11), CD86 (GL1), CD84 (mCD84.7), ICOSL (HK5.3), SLAM (TC15-T2F12.2), Ly108 (330-A5), CXCR5 (2G8), PD-1 (543), CD45.1 (A20), CD45.2 (104), MHCII (25-9-17), CD40 (3/23), CD69 (H1-2F3).</p><p>Data was acquired on LSR Fortessa (BD Bioscience) and analyzed with FlowJo (Treestar, Ashland, Oregon).</p></sec><sec id="s4-8"><title>Protein biotinylation</title><p>Ovalbumin (OVA, Calbiochem) or hen egg lysozyme (HEL, Sigma-Aldrich) were used at a concentration of 1 mg.mL-1 in PBS and mixed for 30 min at room temperature with EZ Link-Sulfo-NHS-Biotin reagent (Pierce). For monobiotinylation, typical concentrations of 0.01 μg.mL-1, 0.02 μg.mL-1, 0.05 μg.mL-1. For poly-biotinylation, higher concentrations, ranging from 0.5 to 1 μg.mL-1 were used. Excess free NHS-biotin was excluded by dialysing the mixtures in PBS overnight at 4°C.</p><p>The degree of biotinylation was tested by flow cytometry. To this end, dialysed antibodies were incubated for 20 min at room temperature with 5.6 μm streptavidin polystyrene beads. Known mono- and poly-biotinylated antibodies were used as negative and positive controls, respectively. Antibodies coupled to beads were detected using FITC-conjugated anti-rat secondary antibodies, and additional free biotin sites were detected using Streptavidin Alexa Fluor 633. Beads were washed with PBS and analysed by flow cytometry.</p></sec><sec id="s4-9"><title>Beads preparation</title><p>Unlabelled (0.11 µM diameter) or AlexaFluor 647 (0.22 µM diameter) streptavidin coated microspheres (Bangs laboratories, Fishers, Indiana) were incubated with saturating amount (as determined from manufacturer’s instructions) of biotinylated anti-IgM (Southern Biotech) or HEL and Ovalbumin (Calbiochem) or Eα peptide for 1 hr at 37°C. Limiting stimulatory conditions were obtained by increasing the amounts of Ova or Eα peptide for coating while IgM amounts were kept constant. Efficient titration of the IgM signal was measured by flow cytometry. For ex vivo internalisation assays, beads coated with anti-IgM alone were used.</p></sec><sec id="s4-10"><title>In vivo B cell activation</title><p>WT and <italic>Itsn2<sup>-/-</sup></italic> B cells labelled in CFSE or CTV (colour-switched experiments were performed systematically) were transferred to C57BL6 (for multiphoton and localisation analysis) or C57BL/6.CD45.1 (for in vivo proliferation and short activation experiments) recipients together with OTII T cells (labelled in CFSE or SNARF-1 when specified) in a typical ratio of 2.10<sup>6</sup> B cells for 10<sup>6</sup> T cells. 24 hr after adoptive transfer, recipient animals were immunised with beads coated with HEL and Ovalbumin, either via tail vein injection (for in vivo proliferation and short-term activation experiments), or by intra-footpad injections (for multiphoton and localisation analysis).</p></sec><sec id="s4-11"><title>Antigen internalization and presentation</title><p>For internalization assays, purified B cells were loaded with IgM coated fluorescently-labelled microspheres or with soluble biotinylated anti-IgM (Southern Biotech) on ice for 30 min. Cells were then washed with PBS 2% FCS to remove excess antigen and then incubated for 5 to 30 min at 37°C. After fixation with 2% paraformaldehyde, non-internalised beads or anti-IgM were detected with AlexaFluor450 streptavidin (eBioscience, San Diego, California). In case of bead internalisation, bead-positive cells were selected on the basis of the bead fluorescence.</p><p>To detect antigen presentation, B cells loaded with Eα peptide and IgM coated microspheres were incubated between 3 and 5 hr at 37°C and then fixed in 2% formaldehyde. These cells were then stained with anti-MHCII/Eα antibody (eBioY-Ae, eBioscience), followed by anti-mouse IgG2b antibody staining (Life Technologies) for detection.</p></sec><sec id="s4-12"><title>Proliferation analysis</title><p>CFSE or CTV-labelled cells at a concentration of 10<sup>6</sup> cells per mL were stimulated in complete B cell medium supplemented with combinations of 1–10 µg.mL<sup>−1</sup> anti-IgM F(ab')<sub>2</sub> (Jackson Immunoresearch, West Grove, Pennsylvania), 1–10 µg.mL<sup>−1</sup> of LPS (Sigma), 0.3–1 µg.mL<sup>−1</sup> CD40L (R and D systems, Minneapolis, Minnesota) or 0.3–3 µg.mL<sup>−1</sup> CpG (ODN1826, Sigma), 10 ng.mL<sup>−1</sup> of IL4 (R and D systems) or 10 ng.mL<sup>−1</sup> of IL5 (R and D systems). CFSE or CTV dilution was measured after 3 or 4 days by flow cytometry.</p><p>For B-T coculture, CTV-labelled B cells were loaded with beads coated with IgM and OVA for 30 min at 37°C in complete medium, then washed with complete medium to remove excess microspheres and subsequently cultured with CFSE-labelled OTII T cells in a 1:1 ratio. B and T cell proliferation were measured after 3 days by flow cytometry.</p></sec><sec id="s4-13"><title>Immunoprecipitation and western blotting</title><p>Purified B cells were left at 37°C for 10 min in chamber buffer (PBS, 0.5% FCS, 1 g.L<sup>−1</sup> D-Glucose, 2 mM MgCl2, 0.5 mM CaCl2) to equilibrate prior to stimulation. They were then stimulated for various times with 10 µg.mL<sup>−1</sup> anti-IgM F(ab’)<sub>2</sub> fragment (Jackson Immunoresearch), prior to lysis in protein lysis buffer (20 mM Tris-HCL, pH 8, 150 mM NaCl, 5 mM EDTA, Protease Inhibitor cocktail (Roche, Switzerland), Phosphatase inhibitors (10 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>), 1% NP40) for 30 min on ice. Lysates were subsequently centrifuged for 15 min at maximum speed on a tabletop centrifuge, and post-nuclear supernatants used for further analysis.</p><p>For immunoprecipitation, post-nuclear supernatants were immunoprecipitated with the 4G10 Ab (Millipore) prebound to protein G-Sepharose beads (Sigma). After gentle rotation at 4°C for 2 hr, the beads were washed five times with protein lysis buffer, and bound proteins were eluted with Laemmli buffer.</p><p>After addition of 2X Laemmli buffer and denaturation at 95°C for 5 min, samples were resolved by SDS-PAGE on precast minigels (7.5% or 12% Tris-HCl; Bio-Rad, Hercules, California), and transferred electrophoretically to PVDF filters using the Miniprotean Transblot system (Bio-Rad). Membranes were incubated in WB blocking buffer (5% milk in TBS, 0.1% Tween) to block non-specific binding, and probed with specific Abs diluted in WB blocking buffer or 5% BSA in TBS-T. Primary antibodies used were specific for ITSN2 (Novus, St-Louis, Missouri, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11038593">AB_11038593</ext-link>), α-tubulin (Sigma), ERK (Cell Signaling Technology, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_330744">AB_330744</ext-link>), phospho-ERK (Cell Signaling Technology, Danvers, Massachussets, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_331646">AB_331646</ext-link>), phospho-Akt-S (Cell Signaling Technology, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_329825">AB_329825</ext-link>), phospho-SHP1 (Cell Signaling Technology, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11141050">AB_11141050</ext-link>), phospho-CD19 (Cell Signaling Technology, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2072836">AB_2072836</ext-link>). After extensive washing in TBS-T, the membranes were incubated with HRP-labeled goat anti-mouse Ig or goat anti-rabbit Ig Abs (Jackson Immunoresearch), and immunoreactivity was visualised by using the ECL system (Amersham Biosciences).</p><p>Densitometric analysis of the films was performed using the Image J software.</p></sec><sec id="s4-14"><title>Optical microscopy</title><p>Planar lipid bilayers containing anti-mouse κ light chain (HB-58; American Type Culture Collection) were prepared in FCS2 chambers (Bioptechs Inc., Butler, Pennsylvania) by liposome spreading as previously described (<xref ref-type="bibr" rid="bib9">Carrasco et al., 2004</xref>). Briefly, Alexa-633 streptavidin (Molecular Probes, Eugene, Oregon) was incorporated into lipid bilayers at density of 30 molecules/μm<sup>2</sup>, to which mono-biotinylated antigen was tethered. Assays were performed in chamber buffer at 37°C and imaged with TIRFM.</p><p>For spreading analysis, cells were settled on coverslips coated either with anti-κ chain antibody (HB-58; American Type Culture Collection), or anti MHCII antibody (TIB120; American Type Culture Collection) at 37°C. After 10 min, cells were fixed with prewarmed 2% paraformaldehyde, permeabilised with PBS 0.1% Triton for 1 min and stained with Alexa Fluor 488 phalloidin (Molecular Probes).</p><p>TIRF images were acquired with an EMCCD camera (iXon3 897, Andor, Northern Ireland) coupled to a TIRF microscopy system (Cell R; Olympus, Japan) with 488 nm, 561 nm and 640 nm lasers (Olympus). Images were recorded with Cell R software (Olympus) and analyzed with ImageJ software (NIH).</p><p>Lymph nodes and spleen were embedded in OCT and frozen in cold isopentane. 10 µm wide frozen sections were cut with a cryostat. Sections were fixed in 4% paraformaldehyde, blocked with PBS containing 1% BSA and 10% goat serum (IF blocking buffer). Staining was performed in IF blocking buffer with a combination of the following antibodies: GL7-AF647, B220 PB (RA3-6B2), TCRβ FITC or PE (H57-597), anti-κ PE (187.1), F4/80 APC (BM8). Confocal imaging was performed with a Zeiss LSM 780 microscope, using a 20x objective (Plan-Appochromat 20X/0.8NA) for spleen sections or a 40x objective (Plan-Appochromat 20X/1.3NA, oil immersion) for LN sections. Tiled images were stitched using the ZEN software (Zeiss), and analysed in Imaris (Bitplane) or ImageJ (NIH).</p><p>For multiphoton microscopy, explanted popliteal and inguinal lymph nodes were prepared as described (<xref ref-type="bibr" rid="bib8">Carrasco and Batista, 2007</xref>), and imaged with an upright multiphoton microscope (Olympus), a 25X, NA 1.05 water immersion objective, and a pulsed Ti:sapphire laser (Spectra Physics MaiTai HP DeepSee) tuned to 820 nm. Emission wavelengths were detected through band-pass filters of 420–500 nm (CTV), 515–560 nm (CFSE) and 590–650 nm (SNARF-1). Multidimensional movies were analyzed with Imaris. Fluorescence bleed-through into the channel with longer wavelength was removed by subtracting the channel with shorter wavelength. Interaction times were measured using spot colocalization with a distance threshold of 10 µm, using Matlab (The MathWorks, Natick, Massachussets).</p></sec><sec id="s4-15"><title>Experimental data and statistical analysis</title><p>Sample sizes were chosen on the basis of published work in which similar phenotypical characterization and similar defects were reported. Cohort randomization or ‘blinding’ of investigators to sample identity was not done in this study. In some experiments, the data for each study group were compared with Student’s t-test or (when applicable) with a paired t-test and P values were calculated. Normal distribution of samples was assumed on the basis of published studies with analysis similar to ours. All statistical analysis was performed using the Prism software (Graphpad Inc, San Diego, California).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the biological resource unit for animal husbandry (The Francis Crick Institute), the flow cytometry unit (The Francis Crick Institute), and the peptide chemistry unit for synthesis of Eαpeptide (The Francis Crick Institute). The <italic>Itsn2<sup>-/-</sup></italic> strain was generated by the trans-NIH Knock-Out Mouse Project (KOMP) and obtained from the KOMP Repository (<ext-link ext-link-type="uri" xlink:href="http://www.komp.org">www.komp.org</ext-link>). We thank Daniel Lingwood for kindly sharing with us the Hemagglutinin trimer and Flu vaccination protocol.﻿ We thank Beatriz Montaner and Kathrin Kirsch for help with managing animal colonies. We thank Selina J Keppler and all the members of the Lymphocyte Interaction Laboratory for scientific discussions and critical reading of the manuscript. We thank Jan Sondenkamp (The Francis Crick Institute) for imaging the ELISPOT plates. This work was supported by the Francis Crick Institute which receives its core funding from Cancer Research UK (FC001035, <underline>FC001209</underline>), the UK Medical Research Council (FC001035, <underline>FC001209</underline>), and the Wellcome Trust (FC001035, <underline>FC001209</underline>), The Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery of the National Institutes of Health (UM1AI100663), the Phillip T and Susan M Ragon Institute Foundation, a Institute Pasteur–Fondazione Cenci Bolognetti (FG) and a long term fellowship from EMBO (SA).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf2"><p>Reviewing editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation, Acquisition of data, Writing—original draft, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>Acquisition of data, Analysis and interpretation of data, Editing the manuscript</p></fn><fn fn-type="con" id="con3"><p>Acquisition of data, Analysis and interpretation of data, Editing the manuscript</p></fn><fn fn-type="con" id="con4"><p>Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con5"><p>Drafting or revising the manuscript</p></fn><fn fn-type="con" id="con6"><p>Resources, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Acquisition of imaging data and image analysis, editing the manuscript</p></fn><fn fn-type="con" id="con8"><p>Investigation, Writing—original draft, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experiments involving animals were approved by the Animal Ethics Committee of The Francis Crick Institute and the UK Home Office (Project licence nº70/8683), and by the Institutional Animal Care and Use Committee of the United States (2016N00286).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.26556.018</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-26556-transrepform-v1.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amigorena</surname> <given-names>S</given-names></name><name><surname>Drake</surname> <given-names>JR</given-names></name><name><surname>Webster</surname> <given-names>P</given-names></name><name><surname>Mellman</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes</article-title><source>Nature</source><volume>369</volume><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/369113a0</pub-id><pub-id pub-id-type="pmid">8177316</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnden</surname> <given-names>MJ</given-names></name><name><surname>Allison</surname> <given-names>J</given-names></name><name><surname>Heath</surname> <given-names>WR</given-names></name><name><surname>Carbone</surname> <given-names>FR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements</article-title><source>Immunology and Cell Biology</source><volume>76</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1046/j.1440-1711.1998.00709.x</pub-id><pub-id pub-id-type="pmid">9553774</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batista</surname> <given-names>FD</given-names></name><name><surname>Harwood</surname> <given-names>NE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The who, how and where of antigen presentation to B cells</article-title><source>Nature Reviews Immunology</source><volume>9</volume><fpage>15</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1038/nri2454</pub-id><pub-id pub-id-type="pmid">19079135</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batista</surname> <given-names>FD</given-names></name><name><surname>Neuberger</surname> <given-names>MS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate</article-title><source>Immunity</source><volume>8</volume><fpage>751</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80580-4</pub-id><pub-id pub-id-type="pmid">9655489</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burbage</surname> <given-names>M</given-names></name><name><surname>Keppler</surname> <given-names>SJ</given-names></name><name><surname>Gasparrini</surname> <given-names>F</given-names></name><name><surname>Martínez-Martín</surname> <given-names>N</given-names></name><name><surname>Gaya</surname> <given-names>M</given-names></name><name><surname>Feest</surname> <given-names>C</given-names></name><name><surname>Domart</surname> <given-names>MC</given-names></name><name><surname>Brakebusch</surname> <given-names>C</given-names></name><name><surname>Collinson</surname> <given-names>L</given-names></name><name><surname>Bruckbauer</surname> <given-names>A</given-names></name><name><surname>Batista</surname> <given-names>FD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cdc42 is a key regulator of B cell differentiation and is required for antiviral humoral immunity</article-title><source>The Journal of Experimental Medicine</source><volume>212</volume><fpage>53</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1084/jem.20141143</pub-id><pub-id pub-id-type="pmid">25547673</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannons</surname> <given-names>JL</given-names></name><name><surname>Qi</surname> <given-names>H</given-names></name><name><surname>Lu</surname> <given-names>KT</given-names></name><name><surname>Dutta</surname> <given-names>M</given-names></name><name><surname>Gomez-Rodriguez</surname> <given-names>J</given-names></name><name><surname>Cheng</surname> <given-names>J</given-names></name><name><surname>Wakeland</surname> <given-names>EK</given-names></name><name><surname>Germain</surname> <given-names>RN</given-names></name><name><surname>Schwartzberg</surname> <given-names>PL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84</article-title><source>Immunity</source><volume>32</volume><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.01.010</pub-id><pub-id pub-id-type="pmid">20153220</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannons</surname> <given-names>JL</given-names></name><name><surname>Yu</surname> <given-names>LJ</given-names></name><name><surname>Jankovic</surname> <given-names>D</given-names></name><name><surname>Crotty</surname> <given-names>S</given-names></name><name><surname>Horai</surname> <given-names>R</given-names></name><name><surname>Kirby</surname> <given-names>M</given-names></name><name><surname>Anderson</surname> <given-names>S</given-names></name><name><surname>Cheever</surname> <given-names>AW</given-names></name><name><surname>Sher</surname> <given-names>A</given-names></name><name><surname>Schwartzberg</surname> <given-names>PL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>SAP regulates T cell-mediated help for humoral immunity by a mechanism distinct from cytokine regulation</article-title><source>The Journal of Experimental Medicine</source><volume>203</volume><fpage>1551</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1084/jem.20052097</pub-id><pub-id pub-id-type="pmid">16754717</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrasco</surname> <given-names>YR</given-names></name><name><surname>Batista</surname> <given-names>FD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node</article-title><source>Immunity</source><volume>27</volume><fpage>160</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2007.06.007</pub-id><pub-id pub-id-type="pmid">17658276</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrasco</surname> <given-names>YR</given-names></name><name><surname>Fleire</surname> <given-names>SJ</given-names></name><name><surname>Cameron</surname> <given-names>T</given-names></name><name><surname>Dustin</surname> <given-names>ML</given-names></name><name><surname>Batista</surname> <given-names>FD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>LFA-1/ICAM-1 interaction lowers the threshold of B cell activation by facilitating B cell adhesion and synapse formation</article-title><source>Immunity</source><volume>20</volume><fpage>589</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1016/S1074-7613(04)00105-0</pub-id><pub-id pub-id-type="pmid">15142527</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffey</surname> <given-names>AJ</given-names></name><name><surname>Brooksbank</surname> <given-names>RA</given-names></name><name><surname>Brandau</surname> <given-names>O</given-names></name><name><surname>Oohashi</surname> <given-names>T</given-names></name><name><surname>Howell</surname> <given-names>GR</given-names></name><name><surname>Bye</surname> <given-names>JM</given-names></name><name><surname>Cahn</surname> <given-names>AP</given-names></name><name><surname>Durham</surname> <given-names>J</given-names></name><name><surname>Heath</surname> <given-names>P</given-names></name><name><surname>Wray</surname> <given-names>P</given-names></name><name><surname>Pavitt</surname> <given-names>R</given-names></name><name><surname>Wilkinson</surname> <given-names>J</given-names></name><name><surname>Leversha</surname> <given-names>M</given-names></name><name><surname>Huckle</surname> <given-names>E</given-names></name><name><surname>Shaw-Smith</surname> <given-names>CJ</given-names></name><name><surname>Dunham</surname> <given-names>A</given-names></name><name><surname>Rhodes</surname> <given-names>S</given-names></name><name><surname>Schuster</surname> <given-names>V</given-names></name><name><surname>Porta</surname> <given-names>G</given-names></name><name><surname>Yin</surname> <given-names>L</given-names></name><name><surname>Serafini</surname> <given-names>P</given-names></name><name><surname>Sylla</surname> <given-names>B</given-names></name><name><surname>Zollo</surname> <given-names>M</given-names></name><name><surname>Franco</surname> <given-names>B</given-names></name><name><surname>Bolino</surname> <given-names>A</given-names></name><name><surname>Seri</surname> <given-names>M</given-names></name><name><surname>Lanyi</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>JR</given-names></name><name><surname>Webster</surname> <given-names>D</given-names></name><name><surname>Harris</surname> <given-names>A</given-names></name><name><surname>Lenoir</surname> <given-names>G</given-names></name><name><surname>de St Basile</surname> <given-names>G</given-names></name><name><surname>Jones</surname> <given-names>A</given-names></name><name><surname>Behloradsky</surname> <given-names>BH</given-names></name><name><surname>Achatz</surname> <given-names>H</given-names></name><name><surname>Murken</surname> <given-names>J</given-names></name><name><surname>Fassler</surname> <given-names>R</given-names></name><name><surname>Sumegi</surname> <given-names>J</given-names></name><name><surname>Romeo</surname> <given-names>G</given-names></name><name><surname>Vaudin</surname> <given-names>M</given-names></name><name><surname>Ross</surname> <given-names>MT</given-names></name><name><surname>Meindl</surname> <given-names>A</given-names></name><name><surname>Bentley</surname> <given-names>DR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene</article-title><source>Nature Genetics</source><volume>20</volume><fpage>129</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1038/2424</pub-id><pub-id pub-id-type="pmid">9771704</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotty</surname> <given-names>S</given-names></name><name><surname>Kersh</surname> <given-names>EN</given-names></name><name><surname>Cannons</surname> <given-names>J</given-names></name><name><surname>Schwartzberg</surname> <given-names>PL</given-names></name><name><surname>Ahmed</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>SAP is required for generating long-term humoral immunity</article-title><source>Nature</source><volume>421</volume><fpage>282</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1038/nature01318</pub-id><pub-id pub-id-type="pmid">12529646</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotty</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A brief history of T cell help to B cells</article-title><source>Nature Reviews Immunology</source><volume>15</volume><fpage>185</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1038/nri3803</pub-id><pub-id pub-id-type="pmid">25677493</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyster</surname> <given-names>JG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>B cell follicles and antigen encounters of the third kind</article-title><source>Nature Immunology</source><volume>11</volume><fpage>989</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1038/ni.1946</pub-id><pub-id pub-id-type="pmid">20959804</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czar</surname> <given-names>MJ</given-names></name><name><surname>Kersh</surname> <given-names>EN</given-names></name><name><surname>Mijares</surname> <given-names>LA</given-names></name><name><surname>Lanier</surname> <given-names>G</given-names></name><name><surname>Lewis</surname> <given-names>J</given-names></name><name><surname>Yap</surname> <given-names>G</given-names></name><name><surname>Chen</surname> <given-names>A</given-names></name><name><surname>Sher</surname> <given-names>A</given-names></name><name><surname>Duckett</surname> <given-names>CS</given-names></name><name><surname>Ahmed</surname> <given-names>R</given-names></name><name><surname>Schwartzberg</surname> <given-names>PL</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP</article-title><source>PNAS</source><volume>98</volume><fpage>7449</fpage><lpage>7454</lpage><pub-id pub-id-type="doi">10.1073/pnas.131193098</pub-id><pub-id pub-id-type="pmid">11404475</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dal Porto</surname> <given-names>JM</given-names></name><name><surname>Gauld</surname> <given-names>SB</given-names></name><name><surname>Merrell</surname> <given-names>KT</given-names></name><name><surname>Mills</surname> <given-names>D</given-names></name><name><surname>Pugh-Bernard</surname> <given-names>AE</given-names></name><name><surname>Cambier</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>B cell antigen receptor signaling 101</article-title><source>Molecular Immunology</source><volume>41</volume><fpage>599</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2004.04.008</pub-id><pub-id pub-id-type="pmid">15219998</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleire</surname> <given-names>SJ</given-names></name><name><surname>Goldman</surname> <given-names>JP</given-names></name><name><surname>Carrasco</surname> <given-names>YR</given-names></name><name><surname>Weber</surname> <given-names>M</given-names></name><name><surname>Bray</surname> <given-names>D</given-names></name><name><surname>Batista</surname> <given-names>FD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>B cell ligand discrimination through a spreading and contraction response</article-title><source>Science</source><volume>312</volume><fpage>738</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1126/science.1123940</pub-id><pub-id pub-id-type="pmid">16675699</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujikawa</surname> <given-names>K</given-names></name><name><surname>Miletic</surname> <given-names>AV</given-names></name><name><surname>Alt</surname> <given-names>FW</given-names></name><name><surname>Faccio</surname> <given-names>R</given-names></name><name><surname>Brown</surname> <given-names>T</given-names></name><name><surname>Hoog</surname> <given-names>J</given-names></name><name><surname>Fredericks</surname> <given-names>J</given-names></name><name><surname>Nishi</surname> <given-names>S</given-names></name><name><surname>Mildiner</surname> <given-names>S</given-names></name><name><surname>Moores</surname> <given-names>SL</given-names></name><name><surname>Brugge</surname> <given-names>J</given-names></name><name><surname>Rosen</surname> <given-names>FS</given-names></name><name><surname>Swat</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells</article-title><source>The Journal of Experimental Medicine</source><volume>198</volume><fpage>1595</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1084/jem.20030874</pub-id><pub-id pub-id-type="pmid">14623913</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerasimcik</surname> <given-names>N</given-names></name><name><surname>Dahlberg</surname> <given-names>CI</given-names></name><name><surname>Baptista</surname> <given-names>MA</given-names></name><name><surname>Massaad</surname> <given-names>MJ</given-names></name><name><surname>Geha</surname> <given-names>RS</given-names></name><name><surname>Westerberg</surname> <given-names>LS</given-names></name><name><surname>Severinson</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The Rho GTPase Cdc42 Is Essential for the Activation and Function of Mature B Cells</article-title><source>The Journal of Immunology</source><volume>194</volume><fpage>4750</fpage><lpage>4758</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401634</pub-id><pub-id pub-id-type="pmid">25870239</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gitlin</surname> <given-names>AD</given-names></name><name><surname>Shulman</surname> <given-names>Z</given-names></name><name><surname>Nussenzweig</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal selection in the germinal centre by regulated proliferation and hypermutation</article-title><source>Nature</source><volume>509</volume><fpage>637</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1038/nature13300</pub-id><pub-id pub-id-type="pmid">24805232</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodnow</surname> <given-names>CC</given-names></name><name><surname>Crosbie</surname> <given-names>J</given-names></name><name><surname>Adelstein</surname> <given-names>S</given-names></name><name><surname>Lavoie</surname> <given-names>TB</given-names></name><name><surname>Smith-Gill</surname> <given-names>SJ</given-names></name><name><surname>Brink</surname> <given-names>RA</given-names></name><name><surname>Pritchard-Briscoe</surname> <given-names>H</given-names></name><name><surname>Wotherspoon</surname> <given-names>JS</given-names></name><name><surname>Loblay</surname> <given-names>RH</given-names></name><name><surname>Raphael</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice</article-title><source>Nature</source><volume>334</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/334676a0</pub-id><pub-id pub-id-type="pmid">3261841</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gryaznova</surname> <given-names>T</given-names></name><name><surname>Kropyvko</surname> <given-names>S</given-names></name><name><surname>Burdyniuk</surname> <given-names>M</given-names></name><name><surname>Gubar</surname> <given-names>O</given-names></name><name><surname>Kryklyva</surname> <given-names>V</given-names></name><name><surname>Tsyba</surname> <given-names>L</given-names></name><name><surname>Rynditch</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Intersectin adaptor proteins are associated with actin-regulating protein WIP in invadopodia</article-title><source>Cellular Signalling</source><volume>27</volume><fpage>1499</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2015.03.006</pub-id><pub-id pub-id-type="pmid">25797047</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>F</given-names></name><name><surname>Velu</surname> <given-names>CS</given-names></name><name><surname>Grimes</surname> <given-names>HL</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Rho GTPase Cdc42 is essential for B-lymphocyte development and activation</article-title><source>Blood</source><volume>114</volume><fpage>2909</fpage><lpage>2916</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-04-214676</pub-id><pub-id pub-id-type="pmid">19671922</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname> <given-names>RR</given-names></name><name><surname>Carmack</surname> <given-names>CE</given-names></name><name><surname>Shinton</surname> <given-names>SA</given-names></name><name><surname>Kemp</surname> <given-names>JD</given-names></name><name><surname>Hayakawa</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow</article-title><source>Journal of Experimental Medicine</source><volume>173</volume><fpage>1213</fpage><lpage>1225</lpage><pub-id pub-id-type="doi">10.1084/jem.173.5.1213</pub-id><pub-id pub-id-type="pmid">1827140</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname> <given-names>BL</given-names></name><name><surname>Harless</surname> <given-names>SM</given-names></name><name><surname>Lindsley</surname> <given-names>RC</given-names></name><name><surname>Hilbert</surname> <given-names>DM</given-names></name><name><surname>Cancro</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators</article-title><source>The Journal of Immunology</source><volume>168</volume><fpage>5993</fpage><lpage>5996</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.168.12.5993</pub-id><pub-id pub-id-type="pmid">12055205</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname> <given-names>AC</given-names></name><name><surname>Donnelly</surname> <given-names>SK</given-names></name><name><surname>Way</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cdc42 and the Rho GEF intersectin-1 collaborate with Nck to promote N-WASP-dependent actin polymerisation</article-title><source>Journal of Cell Science</source><volume>127</volume><fpage>673</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1242/jcs.141366</pub-id><pub-id pub-id-type="pmid">24284073</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kageyama</surname> <given-names>R</given-names></name><name><surname>Cannons</surname> <given-names>JL</given-names></name><name><surname>Zhao</surname> <given-names>F</given-names></name><name><surname>Yusuf</surname> <given-names>I</given-names></name><name><surname>Lao</surname> <given-names>C</given-names></name><name><surname>Locci</surname> <given-names>M</given-names></name><name><surname>Schwartzberg</surname> <given-names>PL</given-names></name><name><surname>Crotty</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The receptor Ly108 functions as a SAP adaptor-dependent on-off switch for T cell help to B cells and NKT cell development</article-title><source>Immunity</source><volume>36</volume><fpage>986</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.05.016</pub-id><pub-id pub-id-type="pmid">22683125</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keerthikumar</surname> <given-names>S</given-names></name><name><surname>Bhadra</surname> <given-names>S</given-names></name><name><surname>Kandasamy</surname> <given-names>K</given-names></name><name><surname>Raju</surname> <given-names>R</given-names></name><name><surname>Ramachandra</surname> <given-names>YL</given-names></name><name><surname>Bhattacharyya</surname> <given-names>C</given-names></name><name><surname>Imai</surname> <given-names>K</given-names></name><name><surname>Ohara</surname> <given-names>O</given-names></name><name><surname>Mohan</surname> <given-names>S</given-names></name><name><surname>Pandey</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Prediction of candidate primary immunodeficiency disease genes using a support vector machine learning approach</article-title><source>DNA Research</source><volume>16</volume><fpage>345</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1093/dnares/dsp019</pub-id><pub-id pub-id-type="pmid">19801557</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keppler</surname> <given-names>SJ</given-names></name><name><surname>Gasparrini</surname> <given-names>F</given-names></name><name><surname>Burbage</surname> <given-names>M</given-names></name><name><surname>Aggarwal</surname> <given-names>S</given-names></name><name><surname>Frederico</surname> <given-names>B</given-names></name><name><surname>Geha</surname> <given-names>RS</given-names></name><name><surname>Way</surname> <given-names>M</given-names></name><name><surname>Bruckbauer</surname> <given-names>A</given-names></name><name><surname>Batista</surname> <given-names>FD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Wiskott-aldrich syndrome interacting protein deficiency uncovers the role of the Co-receptor CD19 as a generic hub for PI3 kinase signaling in B cells</article-title><source>Immunity</source><volume>43</volume><fpage>660</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.09.004</pub-id><pub-id pub-id-type="pmid">26453379</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kitamura</surname> <given-names>D</given-names></name><name><surname>Roes</surname> <given-names>J</given-names></name><name><surname>Kühn</surname> <given-names>R</given-names></name><name><surname>Rajewsky</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene</article-title><source>Nature</source><volume>350</volume><fpage>423</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/350423a0</pub-id><pub-id pub-id-type="pmid">1901381</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koday</surname> <given-names>MT</given-names></name><name><surname>Nelson</surname> <given-names>J</given-names></name><name><surname>Chevalier</surname> <given-names>A</given-names></name><name><surname>Koday</surname> <given-names>M</given-names></name><name><surname>Kalinoski</surname> <given-names>H</given-names></name><name><surname>Stewart</surname> <given-names>L</given-names></name><name><surname>Carter</surname> <given-names>L</given-names></name><name><surname>Nieusma</surname> <given-names>T</given-names></name><name><surname>Lee</surname> <given-names>PS</given-names></name><name><surname>Ward</surname> <given-names>AB</given-names></name><name><surname>Wilson</surname> <given-names>IA</given-names></name><name><surname>Dagley</surname> <given-names>A</given-names></name><name><surname>Smee</surname> <given-names>DF</given-names></name><name><surname>Baker</surname> <given-names>D</given-names></name><name><surname>Fuller</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A computationally designed hemagglutinin stem-binding protein provides in vivo protection from influenza independent of a host immune response</article-title><source>PLOS Pathogens</source><volume>12</volume><elocation-id>e1005409</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005409</pub-id><pub-id pub-id-type="pmid">26845438</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname> <given-names>S</given-names></name><name><surname>Depoil</surname> <given-names>D</given-names></name><name><surname>Martinelli</surname> <given-names>R</given-names></name><name><surname>Judokusumo</surname> <given-names>E</given-names></name><name><surname>Carmona</surname> <given-names>G</given-names></name><name><surname>Gertler</surname> <given-names>FB</given-names></name><name><surname>Kam</surname> <given-names>LC</given-names></name><name><surname>Carman</surname> <given-names>CV</given-names></name><name><surname>Burkhardt</surname> <given-names>JK</given-names></name><name><surname>Irvine</surname> <given-names>DJ</given-names></name><name><surname>Dustin</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Actin foci facilitate activation of the phospholipase C-γ in primary T lymphocytes via the WASP pathway</article-title><source>eLife</source><volume>4</volume><elocation-id>e04953</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.04953</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurosaki</surname> <given-names>T</given-names></name><name><surname>Shinohara</surname> <given-names>H</given-names></name><name><surname>Baba</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>B cell signaling and fate decision</article-title><source>Annual Review of Immunology</source><volume>28</volume><fpage>21</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132541</pub-id><pub-id pub-id-type="pmid">19827951</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanzavecchia</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Antigen-specific interaction between T and B cells</article-title><source>Nature</source><volume>314</volume><fpage>537</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1038/314537a0</pub-id><pub-id pub-id-type="pmid">3157869</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanzi</surname> <given-names>G</given-names></name><name><surname>Moratto</surname> <given-names>D</given-names></name><name><surname>Vairo</surname> <given-names>D</given-names></name><name><surname>Masneri</surname> <given-names>S</given-names></name><name><surname>Delmonte</surname> <given-names>O</given-names></name><name><surname>Paganini</surname> <given-names>T</given-names></name><name><surname>Parolini</surname> <given-names>S</given-names></name><name><surname>Tabellini</surname> <given-names>G</given-names></name><name><surname>Mazza</surname> <given-names>C</given-names></name><name><surname>Savoldi</surname> <given-names>G</given-names></name><name><surname>Montin</surname> <given-names>D</given-names></name><name><surname>Martino</surname> <given-names>S</given-names></name><name><surname>Tovo</surname> <given-names>P</given-names></name><name><surname>Pessach</surname> <given-names>IM</given-names></name><name><surname>Massaad</surname> <given-names>MJ</given-names></name><name><surname>Ramesh</surname> <given-names>N</given-names></name><name><surname>Porta</surname> <given-names>F</given-names></name><name><surname>Plebani</surname> <given-names>A</given-names></name><name><surname>Notarangelo</surname> <given-names>LD</given-names></name><name><surname>Geha</surname> <given-names>RS</given-names></name><name><surname>Giliani</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP</article-title><source>The Journal of Experimental Medicine</source><volume>209</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1084/jem.20110896</pub-id><pub-id pub-id-type="pmid">22231303</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latour</surname> <given-names>S</given-names></name><name><surname>Gish</surname> <given-names>G</given-names></name><name><surname>Helgason</surname> <given-names>CD</given-names></name><name><surname>Humphries</surname> <given-names>RK</given-names></name><name><surname>Pawson</surname> <given-names>T</given-names></name><name><surname>Veillette</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product</article-title><source>Nature Immunology</source><volume>2</volume><fpage>681</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1038/90615</pub-id><pub-id pub-id-type="pmid">11477403</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lessard</surname> <given-names>CJ</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Adrianto</surname> <given-names>I</given-names></name><name><surname>Ice</surname> <given-names>JA</given-names></name><name><surname>Rasmussen</surname> <given-names>A</given-names></name><name><surname>Grundahl</surname> <given-names>KM</given-names></name><name><surname>Kelly</surname> <given-names>JA</given-names></name><name><surname>Dozmorov</surname> <given-names>MG</given-names></name><name><surname>Miceli-Richard</surname> <given-names>C</given-names></name><name><surname>Bowman</surname> <given-names>S</given-names></name><name><surname>Lester</surname> <given-names>S</given-names></name><name><surname>Eriksson</surname> <given-names>P</given-names></name><name><surname>Eloranta</surname> <given-names>ML</given-names></name><name><surname>Brun</surname> <given-names>JG</given-names></name><name><surname>Gøransson</surname> <given-names>LG</given-names></name><name><surname>Harboe</surname> <given-names>E</given-names></name><name><surname>Guthridge</surname> <given-names>JM</given-names></name><name><surname>Kaufman</surname> <given-names>KM</given-names></name><name><surname>Kvarnström</surname> <given-names>M</given-names></name><name><surname>Jazebi</surname> <given-names>H</given-names></name><name><surname>Cunninghame Graham</surname> <given-names>DS</given-names></name><name><surname>Grandits</surname> <given-names>ME</given-names></name><name><surname>Nazmul-Hossain</surname> <given-names>AN</given-names></name><name><surname>Patel</surname> <given-names>K</given-names></name><name><surname>Adler</surname> <given-names>AJ</given-names></name><name><surname>Maier-Moore</surname> <given-names>JS</given-names></name><name><surname>Farris</surname> <given-names>AD</given-names></name><name><surname>Brennan</surname> <given-names>MT</given-names></name><name><surname>Lessard</surname> <given-names>JA</given-names></name><name><surname>Chodosh</surname> <given-names>J</given-names></name><name><surname>Gopalakrishnan</surname> <given-names>R</given-names></name><name><surname>Hefner</surname> <given-names>KS</given-names></name><name><surname>Houston</surname> <given-names>GD</given-names></name><name><surname>Huang</surname> <given-names>AJ</given-names></name><name><surname>Hughes</surname> <given-names>PJ</given-names></name><name><surname>Lewis</surname> <given-names>DM</given-names></name><name><surname>Radfar</surname> <given-names>L</given-names></name><name><surname>Rohrer</surname> <given-names>MD</given-names></name><name><surname>Stone</surname> <given-names>DU</given-names></name><name><surname>Wren</surname> <given-names>JD</given-names></name><name><surname>Vyse</surname> <given-names>TJ</given-names></name><name><surname>Gaffney</surname> <given-names>PM</given-names></name><name><surname>James</surname> <given-names>JA</given-names></name><name><surname>Omdal</surname> <given-names>R</given-names></name><name><surname>Wahren-Herlenius</surname> <given-names>M</given-names></name><name><surname>Illei</surname> <given-names>GG</given-names></name><name><surname>Witte</surname> <given-names>T</given-names></name><name><surname>Jonsson</surname> <given-names>R</given-names></name><name><surname>Rischmueller</surname> <given-names>M</given-names></name><name><surname>Rönnblom</surname> <given-names>L</given-names></name><name><surname>Nordmark</surname> <given-names>G</given-names></name><name><surname>Ng</surname> <given-names>WF</given-names></name><name><surname>Mariette</surname> <given-names>X</given-names></name><name><surname>Anaya</surname> <given-names>JM</given-names></name><name><surname>Rhodus</surname> <given-names>NL</given-names></name><name><surname>Segal</surname> <given-names>BM</given-names></name><name><surname>Scofield</surname> <given-names>RH</given-names></name><name><surname>Montgomery</surname> <given-names>CG</given-names></name><name><surname>Harley</surname> <given-names>JB</given-names></name><name><surname>Sivils</surname> <given-names>KL</given-names></name><collab>UK Primary Sjögren's Syndrome Registry</collab></person-group><year iso-8601-date="2013">2013</year><article-title>Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome</article-title><source>Nature Genetics</source><volume>45</volume><fpage>1284</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1038/ng.2792</pub-id><pub-id pub-id-type="pmid">24097067</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>D</given-names></name><name><surname>Xu</surname> <given-names>H</given-names></name><name><surname>Shih</surname> <given-names>C</given-names></name><name><surname>Wan</surname> <given-names>Z</given-names></name><name><surname>Ma</surname> <given-names>X</given-names></name><name><surname>Ma</surname> <given-names>W</given-names></name><name><surname>Luo</surname> <given-names>D</given-names></name><name><surname>Qi</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction</article-title><source>Nature</source><volume>517</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature13803</pub-id><pub-id pub-id-type="pmid">25317561</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Quiles</surname> <given-names>N</given-names></name><name><surname>Rohatgi</surname> <given-names>R</given-names></name><name><surname>Antón</surname> <given-names>IM</given-names></name><name><surname>Medina</surname> <given-names>M</given-names></name><name><surname>Saville</surname> <given-names>SP</given-names></name><name><surname>Miki</surname> <given-names>H</given-names></name><name><surname>Yamaguchi</surname> <given-names>H</given-names></name><name><surname>Takenawa</surname> <given-names>T</given-names></name><name><surname>Hartwig</surname> <given-names>JH</given-names></name><name><surname>Geha</surname> <given-names>RS</given-names></name><name><surname>Ramesh</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>WIP regulates N-WASP-mediated actin polymerization and filopodium formation</article-title><source>Nature Cell Biology</source><volume>3</volume><fpage>484</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1038/35074551</pub-id><pub-id pub-id-type="pmid">11331876</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCausland</surname> <given-names>MM</given-names></name><name><surname>Yusuf</surname> <given-names>I</given-names></name><name><surname>Tran</surname> <given-names>H</given-names></name><name><surname>Ono</surname> <given-names>N</given-names></name><name><surname>Yanagi</surname> <given-names>Y</given-names></name><name><surname>Crotty</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>SAP regulation of follicular helper CD4 T cell development and humoral immunity is independent of SLAM and Fyn kinase</article-title><source>The Journal of Immunology</source><volume>178</volume><fpage>817</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.2.817</pub-id><pub-id pub-id-type="pmid">17202343</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGhee</surname> <given-names>SA</given-names></name><name><surname>Chatila</surname> <given-names>TA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>DOCK8 immune deficiency as a model for primary cytoskeletal dysfunction</article-title><source>Disease Markers</source><volume>29</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1155/2010/397291</pub-id><pub-id pub-id-type="pmid">21178274</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miceli-Richard</surname> <given-names>C</given-names></name><name><surname>Wang-Renault</surname> <given-names>SF</given-names></name><name><surname>Boudaoud</surname> <given-names>S</given-names></name><name><surname>Busato</surname> <given-names>F</given-names></name><name><surname>Lallemand</surname> <given-names>C</given-names></name><name><surname>Bethune</surname> <given-names>K</given-names></name><name><surname>Belkhir</surname> <given-names>R</given-names></name><name><surname>Nocturne</surname> <given-names>G</given-names></name><name><surname>Mariette</surname> <given-names>X</given-names></name><name><surname>Tost</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome</article-title><source>Annals of the Rheumatic Diseases</source><volume>75</volume><fpage>933</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2014-206998</pub-id><pub-id pub-id-type="pmid">26183421</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname> <given-names>MJ</given-names></name><name><surname>Wei</surname> <given-names>SH</given-names></name><name><surname>Parker</surname> <given-names>I</given-names></name><name><surname>Cahalan</surname> <given-names>MD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Two-photon imaging of lymphocyte motility and antigen response in intact lymph node</article-title><source>Science</source><volume>296</volume><fpage>1869</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1126/science.1070051</pub-id><pub-id pub-id-type="pmid">12016203</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreau</surname> <given-names>V</given-names></name><name><surname>Frischknecht</surname> <given-names>F</given-names></name><name><surname>Reckmann</surname> <given-names>I</given-names></name><name><surname>Vincentelli</surname> <given-names>R</given-names></name><name><surname>Rabut</surname> <given-names>G</given-names></name><name><surname>Stewart</surname> <given-names>D</given-names></name><name><surname>Way</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A complex of N-WASP and WIP integrates signalling cascades that lead to actin polymerization</article-title><source>Nature Cell Biology</source><volume>2</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/35017080</pub-id><pub-id pub-id-type="pmid">10878810</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname> <given-names>R</given-names></name><name><surname>Schmitt</surname> <given-names>N</given-names></name><name><surname>Bentebibel</surname> <given-names>SE</given-names></name><name><surname>Ranganathan</surname> <given-names>R</given-names></name><name><surname>Bourdery</surname> <given-names>L</given-names></name><name><surname>Zurawski</surname> <given-names>G</given-names></name><name><surname>Foucat</surname> <given-names>E</given-names></name><name><surname>Dullaers</surname> <given-names>M</given-names></name><name><surname>Oh</surname> <given-names>S</given-names></name><name><surname>Sabzghabaei</surname> <given-names>N</given-names></name><name><surname>Lavecchio</surname> <given-names>EM</given-names></name><name><surname>Punaro</surname> <given-names>M</given-names></name><name><surname>Pascual</surname> <given-names>V</given-names></name><name><surname>Banchereau</surname> <given-names>J</given-names></name><name><surname>Ueno</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion</article-title><source>Immunity</source><volume>34</volume><fpage>108</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.12.012</pub-id><pub-id pub-id-type="pmid">21215658</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novokhatska</surname> <given-names>O</given-names></name><name><surname>Dergai</surname> <given-names>M</given-names></name><name><surname>Houssin</surname> <given-names>N</given-names></name><name><surname>Tsyba</surname> <given-names>L</given-names></name><name><surname>Moreau</surname> <given-names>J</given-names></name><name><surname>Rynditch</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Intersectin 2 nucleotide exchange factor regulates Cdc42 activity during Xenopus early development</article-title><source>Biochemical and Biophysical Research Communications</source><volume>408</volume><fpage>663</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.04.081</pub-id><pub-id pub-id-type="pmid">21530493</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novokhatska</surname> <given-names>O</given-names></name><name><surname>Dergai</surname> <given-names>M</given-names></name><name><surname>Tsyba</surname> <given-names>L</given-names></name><name><surname>Skrypkina</surname> <given-names>I</given-names></name><name><surname>Filonenko</surname> <given-names>V</given-names></name><name><surname>Moreau</surname> <given-names>J</given-names></name><name><surname>Rynditch</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Adaptor proteins intersectin 1 and 2 bind similar proline-rich ligands but are differentially recognized by SH2 domain-containing proteins</article-title><source>PLoS One</source><volume>8</volume><elocation-id>e70546</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0070546</pub-id><pub-id pub-id-type="pmid">23936226</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pucharcos</surname> <given-names>C</given-names></name><name><surname>Estivill</surname> <given-names>X</given-names></name><name><surname>de la Luna</surname> <given-names>S</given-names></name><name><surname>la Luna, de</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Intersectin 2, a new multimodular protein involved in clathrin-mediated endocytosis</article-title><source>FEBS Letters</source><volume>478</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(00)01793-2</pub-id><pub-id pub-id-type="pmid">10922467</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname> <given-names>H</given-names></name><name><surname>Cannons</surname> <given-names>JL</given-names></name><name><surname>Klauschen</surname> <given-names>F</given-names></name><name><surname>Schwartzberg</surname> <given-names>PL</given-names></name><name><surname>Germain</surname> <given-names>RN</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>SAP-controlled T-B cell interactions underlie germinal centre formation</article-title><source>Nature</source><volume>455</volume><fpage>764</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1038/nature07345</pub-id><pub-id pub-id-type="pmid">18843362</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wright</surname> <given-names>J</given-names></name><name><surname>Agarwala</surname> <given-names>V</given-names></name><name><surname>Scott</surname> <given-names>DA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome engineering using the CRISPR-Cas9 system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randall</surname> <given-names>KL</given-names></name><name><surname>Lambe</surname> <given-names>T</given-names></name><name><surname>Johnson</surname> <given-names>AL</given-names></name><name><surname>Johnson</surname> <given-names>A</given-names></name><name><surname>Treanor</surname> <given-names>B</given-names></name><name><surname>Kucharska</surname> <given-names>E</given-names></name><name><surname>Domaschenz</surname> <given-names>H</given-names></name><name><surname>Whittle</surname> <given-names>B</given-names></name><name><surname>Tze</surname> <given-names>LE</given-names></name><name><surname>Enders</surname> <given-names>A</given-names></name><name><surname>Crockford</surname> <given-names>TL</given-names></name><name><surname>Bouriez-Jones</surname> <given-names>T</given-names></name><name><surname>Alston</surname> <given-names>D</given-names></name><name><surname>Cyster</surname> <given-names>JG</given-names></name><name><surname>Lenardo</surname> <given-names>MJ</given-names></name><name><surname>Mackay</surname> <given-names>F</given-names></name><name><surname>Deenick</surname> <given-names>EK</given-names></name><name><surname>Tangye</surname> <given-names>SG</given-names></name><name><surname>Chan</surname> <given-names>TD</given-names></name><name><surname>Camidge</surname> <given-names>T</given-names></name><name><surname>Brink</surname> <given-names>R</given-names></name><name><surname>Vinuesa</surname> <given-names>CG</given-names></name><name><surname>Batista</surname> <given-names>FD</given-names></name><name><surname>Cornall</surname> <given-names>RJ</given-names></name><name><surname>Goodnow</surname> <given-names>CC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production</article-title><source>Nature Immunology</source><volume>10</volume><fpage>1283</fpage><lpage>1291</lpage><pub-id pub-id-type="doi">10.1038/ni.1820</pub-id><pub-id pub-id-type="pmid">19898472</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudensky AYu</surname></name><name><surname>Rath</surname> <given-names>S</given-names></name><name><surname>Preston-Hurlburt</surname> <given-names>P</given-names></name><name><surname>Murphy</surname> <given-names>DB</given-names></name><name><surname>Janeway</surname> <given-names>CA</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>On the complexity of self</article-title><source>Nature</source><volume>353</volume><fpage>660</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1038/353660a0</pub-id><pub-id pub-id-type="pmid">1656278</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruusala</surname> <given-names>A</given-names></name><name><surname>Aspenström</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Isolation and characterisation of DOCK8, a member of the DOCK180-related regulators of cell morphology</article-title><source>FEBS Letters</source><volume>572</volume><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2004.06.095</pub-id><pub-id pub-id-type="pmid">15304341</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saci</surname> <given-names>A</given-names></name><name><surname>Carpenter</surname> <given-names>CL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>RhoA GTPase regulates B cell receptor signaling</article-title><source>Molecular Cell</source><volume>17</volume><fpage>205</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2004.12.012</pub-id><pub-id pub-id-type="pmid">15664190</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayos</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>C</given-names></name><name><surname>Morra</surname> <given-names>M</given-names></name><name><surname>Wang</surname> <given-names>N</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Allen</surname> <given-names>D</given-names></name><name><surname>van Schaik</surname> <given-names>S</given-names></name><name><surname>Notarangelo</surname> <given-names>L</given-names></name><name><surname>Geha</surname> <given-names>R</given-names></name><name><surname>Roncarolo</surname> <given-names>MG</given-names></name><name><surname>Oettgen</surname> <given-names>H</given-names></name><name><surname>De Vries</surname> <given-names>JE</given-names></name><name><surname>Aversa</surname> <given-names>G</given-names></name><name><surname>Terhorst</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM</article-title><source>Nature</source><volume>395</volume><fpage>462</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/26683</pub-id><pub-id pub-id-type="pmid">9774102</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiemann</surname> <given-names>B</given-names></name><name><surname>Gommerman</surname> <given-names>JL</given-names></name><name><surname>Vora</surname> <given-names>K</given-names></name><name><surname>Cachero</surname> <given-names>TG</given-names></name><name><surname>Shulga-Morskaya</surname> <given-names>S</given-names></name><name><surname>Dobles</surname> <given-names>M</given-names></name><name><surname>Frew</surname> <given-names>E</given-names></name><name><surname>Scott</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway</article-title><source>Science</source><volume>293</volume><fpage>2111</fpage><lpage>2114</lpage><pub-id pub-id-type="doi">10.1126/science.1061964</pub-id><pub-id pub-id-type="pmid">11509691</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartzberg</surname> <given-names>PL</given-names></name><name><surname>Mueller</surname> <given-names>KL</given-names></name><name><surname>Qi</surname> <given-names>H</given-names></name><name><surname>Cannons</surname> <given-names>JL</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>SLAM receptors and SAP influence lymphocyte interactions, development and function</article-title><source>Nature Reviews Immunology</source><volume>9</volume><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/nri2456</pub-id><pub-id pub-id-type="pmid">19079134</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shulman</surname> <given-names>Z</given-names></name><name><surname>Gitlin</surname> <given-names>AD</given-names></name><name><surname>Targ</surname> <given-names>S</given-names></name><name><surname>Jankovic</surname> <given-names>M</given-names></name><name><surname>Pasqual</surname> <given-names>G</given-names></name><name><surname>Nussenzweig</surname> <given-names>MC</given-names></name><name><surname>Victora</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>T follicular helper cell dynamics in germinal centers</article-title><source>Science</source><volume>341</volume><fpage>673</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1126/science.1241680</pub-id><pub-id pub-id-type="pmid">23887872</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skarnes</surname> <given-names>WC</given-names></name><name><surname>Rosen</surname> <given-names>B</given-names></name><name><surname>West</surname> <given-names>AP</given-names></name><name><surname>Koutsourakis</surname> <given-names>M</given-names></name><name><surname>Bushell</surname> <given-names>W</given-names></name><name><surname>Iyer</surname> <given-names>V</given-names></name><name><surname>Mujica</surname> <given-names>AO</given-names></name><name><surname>Thomas</surname> <given-names>M</given-names></name><name><surname>Harrow</surname> <given-names>J</given-names></name><name><surname>Cox</surname> <given-names>T</given-names></name><name><surname>Jackson</surname> <given-names>D</given-names></name><name><surname>Severin</surname> <given-names>J</given-names></name><name><surname>Biggs</surname> <given-names>P</given-names></name><name><surname>Fu</surname> <given-names>J</given-names></name><name><surname>Nefedov</surname> <given-names>M</given-names></name><name><surname>de Jong</surname> <given-names>PJ</given-names></name><name><surname>Stewart</surname> <given-names>AF</given-names></name><name><surname>Bradley</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A conditional knockout resource for the genome-wide study of mouse gene function</article-title><source>Nature</source><volume>474</volume><fpage>337</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1038/nature10163</pub-id><pub-id pub-id-type="pmid">21677750</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname> <given-names>KE</given-names></name><name><surname>Mullen</surname> <given-names>CA</given-names></name><name><surname>Blaese</surname> <given-names>RM</given-names></name><name><surname>Winkelstein</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>A multiinstitutional survey of the Wiskott-Aldrich syndrome</article-title><source>The Journal of Pediatrics</source><volume>125</volume><fpage>876</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1016/S0022-3476(05)82002-5</pub-id><pub-id pub-id-type="pmid">7996359</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarakhovsky</surname> <given-names>A</given-names></name><name><surname>Turner</surname> <given-names>M</given-names></name><name><surname>Schaal</surname> <given-names>S</given-names></name><name><surname>Mee</surname> <given-names>PJ</given-names></name><name><surname>Duddy</surname> <given-names>LP</given-names></name><name><surname>Rajewsky</surname> <given-names>K</given-names></name><name><surname>Tybulewicz</surname> <given-names>VL</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav</article-title><source>Nature</source><volume>374</volume><fpage>467</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1038/374467a0</pub-id><pub-id pub-id-type="pmid">7700358</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrasher</surname> <given-names>AJ</given-names></name><name><surname>Burns</surname> <given-names>SO</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>WASP: a key immunological multitasker</article-title><source>Nature Reviews Immunology</source><volume>10</volume><fpage>182</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1038/nri2724</pub-id><pub-id pub-id-type="pmid">20182458</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valenzuela</surname> <given-names>DM</given-names></name><name><surname>Murphy</surname> <given-names>AJ</given-names></name><name><surname>Frendewey</surname> <given-names>D</given-names></name><name><surname>Gale</surname> <given-names>NW</given-names></name><name><surname>Economides</surname> <given-names>AN</given-names></name><name><surname>Auerbach</surname> <given-names>W</given-names></name><name><surname>Poueymirou</surname> <given-names>WT</given-names></name><name><surname>Adams</surname> <given-names>NC</given-names></name><name><surname>Rojas</surname> <given-names>J</given-names></name><name><surname>Yasenchak</surname> <given-names>J</given-names></name><name><surname>Chernomorsky</surname> <given-names>R</given-names></name><name><surname>Boucher</surname> <given-names>M</given-names></name><name><surname>Elsasser</surname> <given-names>AL</given-names></name><name><surname>Esau</surname> <given-names>L</given-names></name><name><surname>Zheng</surname> <given-names>J</given-names></name><name><surname>Griffiths</surname> <given-names>JA</given-names></name><name><surname>Wang</surname> <given-names>X</given-names></name><name><surname>Su</surname> <given-names>H</given-names></name><name><surname>Xue</surname> <given-names>Y</given-names></name><name><surname>Dominguez</surname> <given-names>MG</given-names></name><name><surname>Noguera</surname> <given-names>I</given-names></name><name><surname>Torres</surname> <given-names>R</given-names></name><name><surname>Macdonald</surname> <given-names>LE</given-names></name><name><surname>Stewart</surname> <given-names>AF</given-names></name><name><surname>DeChiara</surname> <given-names>TM</given-names></name><name><surname>Yancopoulos</surname> <given-names>GD</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>High-throughput engineering of the mouse genome coupled with high-resolution expression analysis</article-title><source>Nature Biotechnology</source><volume>21</volume><fpage>652</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1038/nbt822</pub-id><pub-id pub-id-type="pmid">12730667</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Victora</surname> <given-names>GD</given-names></name><name><surname>Mesin</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Clonal and cellular dynamics in germinal centers</article-title><source>Current Opinion in Immunology</source><volume>28</volume><fpage>90</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2014.02.010</pub-id><pub-id pub-id-type="pmid">24681449</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinuesa</surname> <given-names>CG</given-names></name><name><surname>Cyster</surname> <given-names>JG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>How T cells earn the follicular rite of passage</article-title><source>Immunity</source><volume>35</volume><fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.11.001</pub-id><pub-id pub-id-type="pmid">22118524</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walmsley</surname> <given-names>MJ</given-names></name><name><surname>Ooi</surname> <given-names>SK</given-names></name><name><surname>Reynolds</surname> <given-names>LF</given-names></name><name><surname>Smith</surname> <given-names>SH</given-names></name><name><surname>Ruf</surname> <given-names>S</given-names></name><name><surname>Mathiot</surname> <given-names>A</given-names></name><name><surname>Vanes</surname> <given-names>L</given-names></name><name><surname>Williams</surname> <given-names>DA</given-names></name><name><surname>Cancro</surname> <given-names>MP</given-names></name><name><surname>Tybulewicz</surname> <given-names>VL</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Critical roles for Rac1 and Rac2 GTPases in B cell development and signaling</article-title><source>Science</source><volume>302</volume><fpage>459</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1126/science.1089709</pub-id><pub-id pub-id-type="pmid">14564011</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerberg</surname> <given-names>LS</given-names></name><name><surname>Dahlberg</surname> <given-names>C</given-names></name><name><surname>Baptista</surname> <given-names>M</given-names></name><name><surname>Moran</surname> <given-names>CJ</given-names></name><name><surname>Detre</surname> <given-names>C</given-names></name><name><surname>Keszei</surname> <given-names>M</given-names></name><name><surname>Eston</surname> <given-names>MA</given-names></name><name><surname>Alt</surname> <given-names>FW</given-names></name><name><surname>Terhorst</surname> <given-names>C</given-names></name><name><surname>Notarangelo</surname> <given-names>LD</given-names></name><name><surname>Snapper</surname> <given-names>SB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Wiskott-Aldrich syndrome protein (WASP) and N-WASP are critical for peripheral B-cell development and function</article-title><source>Blood</source><volume>119</volume><fpage>3966</fpage><lpage>3974</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-09-308197</pub-id><pub-id pub-id-type="pmid">22411869</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname> <given-names>I</given-names></name><name><surname>Kageyama</surname> <given-names>R</given-names></name><name><surname>Monticelli</surname> <given-names>L</given-names></name><name><surname>Johnston</surname> <given-names>RJ</given-names></name><name><surname>Ditoro</surname> <given-names>D</given-names></name><name><surname>Hansen</surname> <given-names>K</given-names></name><name><surname>Barnett</surname> <given-names>B</given-names></name><name><surname>Crotty</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Germinal center T follicular helper cell IL-4 production is dependent on signaling lymphocytic activation molecule receptor (CD150)</article-title><source>The Journal of Immunology</source><volume>185</volume><fpage>190</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903505</pub-id><pub-id pub-id-type="pmid">20525889</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>Q</given-names></name><name><surname>Davis</surname> <given-names>JC</given-names></name><name><surname>Lamborn</surname> <given-names>IT</given-names></name><name><surname>Freeman</surname> <given-names>AF</given-names></name><name><surname>Jing</surname> <given-names>H</given-names></name><name><surname>Favreau</surname> <given-names>AJ</given-names></name><name><surname>Matthews</surname> <given-names>HF</given-names></name><name><surname>Davis</surname> <given-names>J</given-names></name><name><surname>Turner</surname> <given-names>ML</given-names></name><name><surname>Uzel</surname> <given-names>G</given-names></name><name><surname>Holland</surname> <given-names>SM</given-names></name><name><surname>Su</surname> <given-names>HC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Combined immunodeficiency associated with DOCK8 mutations</article-title><source>New England Journal of Medicine</source><volume>361</volume><fpage>2046</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0905506</pub-id><pub-id pub-id-type="pmid">19776401</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname> <given-names>M</given-names></name><name><surname>Qu</surname> <given-names>D</given-names></name><name><surname>Wang</surname> <given-names>H</given-names></name><name><surname>Sun</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>J</given-names></name><name><surname>Li</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Intranasal administration of chitosan against influenza a (h7n9) virus infection in a mouse model</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>28729</elocation-id><pub-id pub-id-type="doi">10.1038/srep28729</pub-id><pub-id pub-id-type="pmid">27353250</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.26556.022</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Dustin</surname><given-names>Michael L</given-names></name><role>Reviewing Editor</role><aff><institution>University of Oxford</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Tuning of in vivo cognate B-T cell interactions by Intersectin 2 is required for effective anti-viral B cell immunity&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, one of whom, Michael L Dustin is a member of our Board of Reviewing Editors and the evaluation has been overseen by Michel Nussenzweig as the Senior Editor.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>In this study, Burbage and colleagues explore the role of ITSN2, an SH3- containing adaptor protein and a Cdc42 GEF that is associated with Sjogren's syndrome, in B cell activation, germinal center development, and antibody responses against model antigen and viral infection. The study is quite comprehensive and touches on multiple potentially interesting and important topics of the field (e.g. a new player mediating specialized signals downstream of BCR for activation and/or antigen uptake; potential involvement of B-cell cytoskeleton dynamics in regulation of antigen-specific T:B interactions). However, despite a multitude of phenotypes observed in association with the ITSN2 deficiency, mechanistic analyses remain superficial and fragmented. In fact, different parts of the study are not so well connected to one another, and as a whole the study cannot yet reach a firm conclusion on the role of ITSN2 at the cellular, tissue, or the organismal level.</p><p>Essential revisions:</p><p>1) Although ITSN2 KO mice show an increased susceptibility to PR8 infection within the first 3-6 days, it is too acute to be explained by potentially abnormal B-cell activation or defective germinal center development (observed on day 7 in <xref ref-type="fig" rid="fig2">Figure 2</xref>). The readers are left wondering exactly how this phenotype is connected to later parts of the paper, particularly those mechanistic studies. The reviewers could envision two ways to address this gap. (1) its known that natural antibodies and complement play a role in protection of naive mice against flu infection (see Jayasekera, Moseman and Carroll, 2007). The authors surprisingly don't report on basal serum antibodies and ability of these to neutralize the PR8 virus in vitro. If this information is provided and accounts for the early defect then this could be reported as an additional defect that would connect the resistance to flu to a B cell defect and would be sufficient to go forward with studies of vaccination responses. (2) Since most of the study focuses on germinal center and recall responses, could the flu infection be done in the context of vaccination looking for lack of or partly defective protection to re-infection? This could also address the gap, although perhaps the data could be presented after the analysis of GC reactions.</p><p>2) These authors suspected antigen uptake/processing might be impaired in the absence of ITSN2, and three assays in vitro, namely, BCR internalization, direct detection of surface pMHC complexes, and T cell-driven B cell proliferation in culture to test if ITSN2 is required for efficient BCR-mediated antigen uptake and presentation (Figure 7—figure supplement 1). These are important and appropriate assays, especially given the subsequent observation of defective T:B interactions in vivo (Figure 8). However, it is VERY difficult for these in vitro assays to mimic the level of antigen availability and the stringent requirement for cognate T cells that antigen-specific B cells may experience in vivo. The fact that an effect of ITSN2 was not apparent in those in vitro assays may still reflect a sensitivity issue. They should try to test BCR internalization and pMHC levels on WT and ITSN2 KO B cells activated in vivo as in <xref ref-type="fig" rid="fig7">Figure 7A</xref>. Also, they should include a group without T cell co-transfer in <xref ref-type="fig" rid="fig7">Figure 7A</xref> to ensure the difference in proliferation seen is T cell-dependent. It is really hard to conceptualize that differences in CD84, SLAM, and ICOSL as seen in <xref ref-type="fig" rid="fig7">Figure 7</xref> can explain the defect in proliferation. It remains the more likely scenario that the ITSN2 deficiency impairs BCR signaling and antigen uptake, leading to defects in antigen-specific T:B interactions. The observation that WT and KO B cells respond to NP-LPS differently (<xref ref-type="fig" rid="fig4">Figure 4F</xref>) also supports the possibility that defects in BCR and/or TLR signaling is a primary defect. The authors should look harder.</p><p>3) Analysis of the ITSN2 impact on BCR signaling is somewhat superficial, and the authors did not offer an explanation for the difference between reduced CD19/PI3K activities and enhanced ERK activation (<xref ref-type="fig" rid="fig6">Figure 6</xref>). What about calcium flux after anti-IgM stimulation? Are any of these pathways more or less important for BCR-mediated antigen uptake and CD84/SLAM/ICOSL expression?</p><p>4) The LN explant imaging data in Figure 8 look solid, although it is important to conduct color-switched experiments to ensure the difference seen is not due to different toxicity profiles of the organic fluorescence dyes?</p><p>5) It is probably important to conduct rescue experiments with ITSN2 overexpression in some of the relevant assays. This is to ensure the effect seen with the ITSN2 deficiency is indeed due to ITSN2 but not LacZ, given how the KOMP knockout was made.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.26556.023</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Although ITSN2 KO mice show an increased susceptibility to PR8 infection within the first 3-6 days, it is too acute to be explained by potentially abnormal B-cell activation or defective germinal center development (observed on day 7 in <xref ref-type="fig" rid="fig2">Figure 2</xref>). The readers are left wondering exactly how this phenotype is connected to later parts of the paper, particularly those mechanistic studies. The reviewers could envision two ways to address this gap. (1) its known that natural antibodies and complement play a role in protection of naive mice against flu infection (see Jayasekera, Moseman and Carroll, 2007). The authors surprisingly don't report on basal serum antibodies and ability of these to neutralize the PR8 virus in vitro. If this information is provided and accounts for the early defect then this could be reported as an additional defect that would connect the resistance to flu to a B cell defect and would be sufficient to go forward with studies of vaccination responses. (2) Since most of the study focuses on germinal center and recall responses, could the flu infection be done in the context of vaccination looking for lack of or partly defective protection to re-infection? This could also address the gap, although perhaps the data could be presented after the analysis of GC reactions.</p></disp-quote><p>We thank the reviewers for highlighting this omission. We have now measured basal serum antibody titres, and found no notable differences between WT and ITSN2 KO animals. This is now shown in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>.</p><p>Our revised version of the manuscript also describes flu infection in the context of vaccination. To address this, we applied a strategy described by Zheng et al., (2016), wherein animals are vaccinated by intravenous injection of hemagglutinin trimer together with Sigma Adjuvant. After 1 month, animals are injected with a lethal dose (1.5x10<sup>5)</sup>of PR8 virus. In response to such challenge, both WT and ITSN2 KO mice exhibited severe weight loss. As expected from this experiment, WT animals started to regain weight at d9 post infection; however, this was not the case for the ITSN2 KO animals, whose weight continued to remain low for the entire duration of the experiment. These results further support the notion that ITSN2 is required for establishing protective responses upon viral infection. They are now presented in <xref ref-type="fig" rid="fig2">Figure 2C</xref>. We believe that these results strengthen our study, and thank the reviewers for highlighting this important point.</p><disp-quote content-type="editor-comment"><p>2) These authors suspected antigen uptake/processing might be impaired in the absence of ITSN2, and three assays in vitro, namely, BCR internalization, direct detection of surface pMHC complexes, and T cell-driven B cell proliferation in culture to test if ITSN2 is required for efficient BCR-mediated antigen uptake and presentation (Figure 7—figure supplement 1). These are important and appropriate assays, especially given the subsequent observation of defective T:B interactions in vivo (Figure 8). However, it is VERY difficult for these in vitro assays to mimic the level of antigen availability and the stringent requirement for cognate T cells that antigen-specific B cells may experience in vivo. The fact that an effect of ITSN2 was not apparent in those in vitro assays may still reflect a sensitivity issue. They should try to test BCR internalization and pMHC levels on WT and ITSN2 KO B cells activated in vivo as in <xref ref-type="fig" rid="fig7">Figure 7A</xref>.</p></disp-quote><p>We thank the reviewers for pointing out these important points. We have indeed measured the presentation of Eα peptide not only in vitro (Figure 7—figure supplement 1A), but also in vivo (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). We have now amended the text and figure legends to state this more explicitly. Moreover, to complement these results, we have now included information regarding the ability of ITSN2 KO B cells to capture particulate antigen in vivo. These data are now presented in (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>, panel F) and discussed in the text.</p><disp-quote content-type="editor-comment"><p>Also, they should include a group without T cell co-transfer in <xref ref-type="fig" rid="fig7">Figure 7A</xref> to ensure the difference in proliferation seen is T cell-dependent.</p></disp-quote><p>in vivo proliferation using Hel-OVA coated beads has been extensively used in our group. To confirm that MD4<sup>+</sup> B cell proliferation is T cell-dependent in this setting, we have performed multiple experiments comparing beads coated with HEL in absence of OVA. Under these conditions, we were unable to detect B cell proliferation, indicating that B cell proliferation is dependent on T cell help. We have attached for the reviewer’s attention, representative results of such experiments (<xref ref-type="fig" rid="respfig1">Author response image 1</xref>), and would be happy to include them as supplementary figures if they feel it would be useful for the clarity of the manuscript.</p><fig id="respfig1"><object-id pub-id-type="doi">10.7554/eLife.26556.020</object-id><label>Author response image 1.</label><caption><title>MD4 B cells and OTII T cells were transferred to WT recipients, and animals immunised with particles coated with HEL alone (black tinted line) or HEL and OVA (Blue line).</title><p>B cells proliferation was measured by FACS at d3.</p></caption><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-26556-resp-fig1-v1"/></fig><disp-quote content-type="editor-comment"><p>It is really hard to conceptualize that differences in CD84, SLAM, and ICOSL as seen in <xref ref-type="fig" rid="fig7">Figure 7</xref> can explain the defect in proliferation. It remains the more likely scenario that the ITSN2 deficiency impairs BCR signaling and antigen uptake, leading to defects in antigen-specific T:B interactions. The observation that WT and KO B cells respond to NP-LPS differently (<xref ref-type="fig" rid="fig4">Figure 4F</xref>) also supports the possibility that defects in BCR and/or TLR signaling is a primary defect. The authors should look harder.</p></disp-quote><p>We thank the reviewers for these comments. We have now analysed B cell proliferation in response to particles coated with IgM and CpG in vitro, and found no differences in the ability of ITSN2 KO and WT B cells to respond to such stimuli. This is now reported in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2.E</xref>,panel E.</p><p>Moreover, we have also explored the long-term consequences of BCR triggering by stimulating WT and ITSN2 KO B cells in vitro in presence of IL4 with or without anti-IgM for 24h. In these settings, we found that ITSN2 KO B cells presented consistently reduced levels of phospho-SHP1, but not phosphor-ERK in presence, but not in absence of anti-IgM. This is now reported in <xref ref-type="fig" rid="fig5">Figure 5F</xref>. These results suggest that ITSN2 deficiency causes long-term differences in BCR signaling.</p><disp-quote content-type="editor-comment"><p>3) Analysis of the ITSN2 impact on BCR signaling is somewhat superficial, and the authors did not offer an explanation for the difference between reduced CD19/PI3K activities and enhanced ERK activation (<xref ref-type="fig" rid="fig6">Figure 6</xref>). What about calcium flux after anti-IgM stimulation?</p></disp-quote><p>We thank the reviewers for their suggestions. We have now analysed calcium signalling upon anti-κ stimulation, and found that calcium flux upon BCR triggering was not impaired in ITSN2 deficient cells. This is now reported in <xref ref-type="fig" rid="fig5">Figure 5D</xref> and discussed in the text.</p><p>We recently described that B cells lacking the WASp interacting protein (WASp) also have defective GC formation and antibody responses, and present with altered PI3K signalling and CD19 phosphorylation, but not ERK activation, downstream BCR engagement, associated with altered BCR motility. To test whether this association could be observed in ITSN2 KO cells, we compared the diffusion coefficient of IgM, IgD and CD19 on WT and ITSN2 KO B cells. We detected a mild increase in CD19 diffusion coefficient in ITSN2 KO B cells, concordant with the model we proposed wherein WIP regulated CD19 phosphorylation by modulating actin dynamics and BCR motility.</p><disp-quote content-type="editor-comment"><p>Are any of these pathways more or less important for BCR-mediated antigen uptake and CD84/SLAM/ICOSL expression?</p></disp-quote><p>Expression of CD84, SLAM and ICOSL is increased in B cells upon activation. Although we could not detect B cell activation defects in vitro upon ITSN2 deletion, we cannot exclude that in vivo, the reduced expression of these receptors on activated ITSN2 KO B cells results from BCR signalling defects.</p><disp-quote content-type="editor-comment"><p>4) The LN explant imaging data in Figure 8 look solid, although it is important to conduct color-switched experiments to ensure the difference seen is not due to different toxicity profiles of the organic fluorescence dyes?</p></disp-quote><p>We thank the reviewers for pointing this out. We have indeed performed color-switched experiments to rule out dye-specific effects and have found similar results. Colour-switched experiments were also performed for all adoptive transfer experiments where WT and ITSN2 KO cells were analysed in the same animal. We now have clarified the legend and material and methods to reflect this important point.</p><disp-quote content-type="editor-comment"><p>5) It is probably important to conduct rescue experiments with ITSN2 overexpression in some of the relevant assays. This is to ensure the effect seen with the ITSN2 deficiency is indeed due to ITSN2 but not LacZ, given how the KOMP knockout was made.</p></disp-quote><p>We thank the reviewers for highlighting this. Upon reception of the ITSN2 KO strain, we performed experiments (development and immunization) comparing WT, Heterozygous and ITSN2 KO animals. We never detected any difference between WT and heterozygous animals, and hence have used heterozygous animals (that express one copy of lacz) as controls in all experiments presented in the paper. We present here (<xref ref-type="fig" rid="respfig2">Author response image 2</xref>) an experiment where ITSN2+/- animals were compared to WT ones in the context of Vaccinia infection, showing germinal centres in the popliteal LN.</p><fig id="respfig2"><object-id pub-id-type="doi">10.7554/eLife.26556.021</object-id><label>Author response image 2.</label><caption><title>WT and ITSN2+/- littermates were infected with 10<sup>4</sup> PFU VACV by intra-footpad injection.</title><p>GC formation was measured in the popliteal LN 7 days after infection.</p></caption><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-26556-resp-fig2-v1"/></fig><p>Moreover, to address this point, we have used CRISPR/Cas9 to ablate ITSN2</p><p>in A20 cells expressing a HEL-specific BCR. In this system, independent of</p><p>LacZ knock-in, we could reproduce the defect in actin foci formation observed</p><p>in primary ITSN2 KO cells. Moreover, complementation of the ITSN2 KO cells</p><p>with ITSN2LGFP was sufficient to restore actin foci formation to the WT level.</p><p>This is now reported in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1.A</xref></p></body></sub-article></article>